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ABSTRACT 
The acute inflammatory response is characterized by recruitment of 
leukocytes and increased vascular permeability, resulting in the cardinal 
signs of inflammation; redness, heat, swelling, pain and loss of function. 
Permeability changes of the vascular wall are important in functional 
immune responses and host defense. On the other hand, derangement of the 
vascular barrier is a principal cause for plasma leakage and edema formation 
in severe disease states such as sepsis, substantially accounting for high 
morbidity and mortality by contributing to organ dysfunction and circulatory 
failure.  Neutrophil granulocytes, a subtype of leukocytes, are first on sight in 
the acute inflammatory response where they adhere to, and migrate through, 
a monolayer of endothelial cells that constitute the innermost layer of the 
vascular wall. Neutrophil-derived proteins, released from activated 
neutrophils, cause endothelial barrier disruption via partly unknown 
mechanisms. Since neutrophil activation and degranulation are considered 
central in the pathogenesis of acute inflammatory disease states, and novel 
treatment strategies are sought after, this thesis work aimed to further 
expand our understanding of mechanisms regulating neutrophil-evoked 
alterations of the endothelial barrier.   
In paper I, the role of the kallikrein-kinin system (KKS) in neutrophil-
induced vascular leakage was investigated. The KKS is a pro-inflammatory 
protein complex found in plasma that is responsible for formation of 
bradykinin (BK), a known inducer of vascular hyperpermeability via binding 
of bradykinin receptors on endothelial cells. In three different in vivo models 
of acute inflammation in two different species, we found that inhibition of 
KKS attenuated neutrophil-mediated plasma leakage. Further, in vitro 
studies with isolated human neutrophils and endothelial cells showed that 
factors secreted from activated neutrophils caused BK-mediated endothelial 
barrier disruption, and that neutrophil-derived heparin-binding protein 
facilitated KKS activation caused by neutrophil granule proteases.  
In paper II, we investigated the therapeutic potential and mode of action of 
the heparin derivative sevuparin in neutrophil-mediated vascular leak caused 
by group A Streptococcus. In vivo and in vitro studies showed that sevuparin 
attenuated endothelial barrier disruption and lung plasma leakage by 
neutralizing neutrophil-derived proteins. Affinity chromatography and mass 
spectrometry were utilized to identify proteins targeted by sevuparin, 
confirming the previously established disruptive role of several neutrophil-
derived proteins on endothelial barrier function.  
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In paper III, we tested the hypothesis that platelet-derived polyphosphates 
(polyP) activate neutrophils, and investigated polyP as a potential 
therapeutic target in acute inflammation. During inflammation, interaction 
of activated platelets with neutrophils results in neutrophil activation. Also, 
platelets are known to release polyP that have been attributed roles in both 
inflammation and coagulation. We found in vitro that polyP induced 
neutrophil degranulation and in vivo that systemic administration of polyP 
caused lung plasma leakage in a neutrophil-dependent manner. 
Furthermore, inhibition of polyP decreased lung plasma leakage in a mouse 
model of acute systemic inflammation induced by group A Streptococcus. 
In paper IV, we set out to investigate the effect of phenylbutyrate (PBA), a 
short-chain fatty acid suggested to have immunomodulatory properties, on 
the inflammatory response in a mouse model of pneumonia with 
Pseudomonas aeruginosa. PBA treatment altered the kinetics of neutrophil 
recruitment in lungs in response to P. aeruginosa resulting in enhanced 
initial mobilization of neutrophils followed by a more rapid decline in cell 
recruitment compared to no treatment. Coincident with the decline in cell 
recruitment, lung edema and protein leakage was reduced. In vitro, PBA was 
found to promote release of neutrophil chemotactic factors from lung 
epithelium.  
In conclusion, this thesis work provides new insights into mechanisms 
regulating endothelial barrier function in neutrophilic inflammation and 
suggests potential therapeutic strategies.  
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Akut inflammation uppstår som en konsekvens av infektion med 
exempelvis bakterier eller virus, eller på grund av vävnadsskada, och 
kännetecknas av rodnad, värmeökning, svullnad, smärta och nedsatt 
vävnadsfunktion. Den akuta inflammationsreaktionen har en viktig funktion 
i att bekämpa infektioner och läka skador, men vid allvarliga 
sjukdomstillstånd såsom sepsis (tidigare kallat blodförgiftning), 
lunginflammation eller stort trauma kan inflammationssvaret bli så starkt att 
det i sig bidrar till ökad sjuklighet och dödlighet. Den akuta 
inflammationsreaktionen börjar med att skadad eller infekterad vävnad 
skickar ut signalmolekyler som aktiverar blodkärl, som i sin tur aktiverar en 
viss typ av vita blodkroppar, så kallade neutrofiler, som cirkulerar i blodet. 
Detta leder till att neutrofiler fäster till endotelceller i kärlväggen för att 
sedan vandra ut från blodkärlet till den infekterade eller skadade vävnaden. 
När detta sker så orsakar neutrofiler, genom att påverka funktionen 
hos endotelceller, ett läckage av vätska och proteiner ut från 
blodkärlet vilket resulterar i svullnad. Denna svullnad kan i vissa fall, 
exempelvis vid chocklunga (ARDS) orsakad av sepsis eller lunginflammation, 
vara så omfattande att den försvårar andning och ger irreversibla skador på 
lungorna.  
I mitt avhandlingsarbete undersökte vi hur plasmaläckage och 
vävnadssvullnad orsakad av aktiverade neutrofiler uppstår vid akut 
inflammation, med målet att hitta nya sätt att motverka 
inflammationssvaret. För att studera detta användes djurmodeller vilka 
representerade olika inflammatoriska tillstånd, framförallt inflammation i 
lungvävnad, samt isolerade endotelceller och neutrofiler från människa.  
I delarbete I fann vi att neutrofil-orsakat plasmaläckage till stor del sker 
genom att aktiverade neutrofiler frisätter proteiner som i sin tur leder till 
bildning av bradykinin. Bradykinin är ett ämne som man sedan tidigare vet 
kan orsaka plasmaläckage genom att påverka endotelceller. Vidare fann vi att 
HBP, ett protein som frisätts från aktiverade neutrofiler, har en särskild roll 
genom att förstärka bildningen av bradykinin. I delarbete II undersökte vi 
ifall läkemedlet sevuparin har effekt på neutrofil-inducerat plasmaläckage 
och vävnadssvullnad. Vi fann att sevuparin motverkar svullnad genom att 
binda specifika proteiner som frisätts från aktiverade neutrofiler och hämma 
aktiviteten hos dessa. 
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Blodplättar finns i blodet och är viktiga för levring av blodet vid blödning. 
Utöver denna funktion så är de också inblandade i den inflammatoriska 
processen. I delarbete III undersökte vi om ämnet polyfosfat (polyP), som 
frisätts från aktiverade blodplättar, kan aktivera neutrofiler. PolyP har 
tidigare visats kunna orsaka vävnadssvullnad med det är inte klarlagt hur. Vi 
fann att polyP aktiverar neutrofiler vilket leder till frisättning av neutrofil-
proteiner och nedsättning av kärlendotelets barriärfunktion.  
I delarbete I-III undersöktes olika mekanismer och potentiella 
behandlingsstrategier med det generella syftet att dämpa ett alltför kraftigt 
inflammationssvar. En annan lovande strategi, som är relevant framförallt 
vid inflammation orsakad av infektion, är behandling med läkemedel som 
kan förbättra immunförsvarets förmåga att bekämpa infektion och främja 
utläkning. I delarbete IV undersökte vi effekten av läkemedlet fenylbutyrat 
(PBA) på inflammationssvaret. Vi fann att PBA modifierar 
inflammationssvaret genom att initialt påskynda ansamlingen av neutrofiler i 
vävnaden, för att sedan orsaka en snabbare minskning av dem. Denna 
minskning sammanföll med minskad vävnadssvullnad.  
Sammantaget så ger denna avhandling ökad kunskap om mekanismer 
bakom neutrofil-orsakat plasmaläckage och vävnadssvullnad vid akut 
inflammation, och pekar på ett flertal potentiella angreppspunkter för att 
motverka läckage från blodkärl vid inflammatoriska sjukdomstillstånd.  
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1.1 INFLAMMATION 
In the case of injury or infection, the host response termed inflammation is 
mobilized. This complex system of events has the common purpose to protect 
and restore tissue function by eliminating infectious pathogens and damaged 
cells, and a functional inflammatory response is crucial for survival. Some 
common causes for initiation of inflammation are infections with 
microorganisms, trauma, allergy, autoimmunity and ischemia (Kumar et al., 
2007). Although the inflammatory response aims to protect and repair, in 
some cases the response is misdirected and/or uncontrolled, which leads to 
host tissue damage so significant that inflammation becomes a major part of 
pathogenesis. Inflammation can be divided into two types, acute and chronic. 
Acute inflammation, which is the focus of this thesis work, is initiated rapidly 
and its severity ranges from minor wounds to critical systemic inflammatory 
conditions with high mortality. Chronic inflammation on the other hand, is a 
prolonged process due to an inability to eliminate the inflammatory factor, 
involving coincident tissue injury and healing. 
1.1.1 THE ACUTE INFLAMMATORY RESPONSE 
The acute inflammatory reaction takes place in the microcirculation and 
encompasses elements of the vascular wall such as endothelial cells (EC) and 
the extracellular matrix, as well as blood-borne elements such as leukocytes, 
platelets and plasma components (Kumar et al., 2007). The classic clinical 
manifestations of inflammation were first established by Aulus Cornelius 
Celsus in the 1st century AD, namely heat (calor), redness (rubor), swelling 
(tumor) and pain (dolor), and in the 19th century Rudolf Virchow contributed 
with the fifth sign: loss of function (functio laesa) (Silva, 1978). All these 
cardinal signs originate from cellular and molecular events in the 
microcirculation. Arteriolar dilation generates increased blood flow causing 
redness and heat, and increased permeability of the vessel wall leads to 
swelling and edema formation by leakage of plasma into extravascular tissue 
(Kumar et al., 2007). Coincidently, release of chemical factors mediates pain 
by the stimulation of nociceptors.  
When tissue becomes injured or infected, the cells of the innate immune 
system in the near environment are exposed to DAMPs or PAMPs 
(damage/pathogen-associated molecular pattern molecules). DAMPs, also 
known as danger signals or alarmins, are endogenous factors such as high 
mobility group box 1 protein, (HMGB1), deoxyribonucleic acid (DNA), 
ribonucleic acid (RNA) and S100 proteins that are released from cells upon 
stress, trauma or ischemia. PAMPs on the other hand are pathogen-derived 
molecules such as lipopolysaccharide (LPS), peptidoglycan and single-
stranded RNA (ssRNA) that are expressed on or released from pathogens. 
  18 
PAMPs and DAMPs are recognized by pathogen recognition receptors 
(PRRs) such as Toll-like receptors (TLR) on immune cells. Tissue-resident 
immune cells such as macrophages, mast cells and dendritic cells then 
initiate the inflammatory response by releasing nitric oxide (NO), histamine, 
prostaglandins, leukotrienes, cytokines and chemokines that affect the cells 
within the vascular wall. NO, histamine and prostaglandins contribute to 
vasodilation by affecting smooth muscle cells, and cytokines stimulate ECs to 
express leukocyte adhesion molecules (Newton and Dixit, 2012). These 
events then contribute to the recruitment of leukocytes that leads to 
extravasation of leukocytes from blood to injured or infected tissue. 
Moreover, prior to and concurrent with leukocyte adhesion to the 
endothelium, vasoactive mediators that increase the permeability of the EC 
barrier are released from affected tissue and leukocytes, leading to leakage of 
plasma out to the extravascular space. Extravasated plasma leads to edema 
formation and contains important components of the immune system such 
as complement factors and immunoglobulins. The fact that the acute 
inflammatory response at its core is a functional response is important to 
emphasize. Inflammation is crucial for a successful immune response since it 
kills pathogens, engulfs damaged cells and paves the way for the adaptive 
immune system. Also, it initiates wound healing and tissue repair.  
1.1.2 ACUTE SYSTEMIC INFLAMMATION AND LUNG INJURY 
However functional the inflammatory response might be, there are occasions 
where it becomes misdirected or uncontrolled. Acute systemic inflammation 
can develop as a consequence of bacterial infection as well as from sterile 
inflammation caused by for example trauma or acute pancreatitis, to name a 
few. Acute systemic inflammation is characterized by increased levels of 
proinflammatory cytokines such as interleukin-1 (IL-1), interleukin 6 (IL-6) 
and tumor necrosis factor (TNF). They are in large responsible for the clinical 
signs fever, leukocytosis and an increase in acute-phase proteins such as C 
reactive protein. In severe cases of both infectious and noninfectious disease, 
cytokine release is so massive that it is referred to as a cytokine storm 
(Tisoncik et al., 2012). This leads to uncontrolled inflammation and 
distributive shock due to systemic effects on blood vessel tone, endothelial 
permeability and leukocytes, resulting in hypotension, leaky vessels and the 
risk of multiple organ dysfunction syndrome (MODS). Organ systems that 
are commonly affected in MODS are lungs, kidneys, liver, the cardiovascular 
system and central nervous system.  
Respiratory failure as a consequence of an acute systemic inflammatory 
response can be defined as acute lung injury (ALI), or the more severe form 
acute respiratory distress syndrome (ARDS). In clinical practice, ARDS is 
diagnosed and graded according to the Berlin definition (Ranieri et al., 2012), 
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a classification system that takes into account the time span of onset of 
respiratory symptoms, radiographic findings on chest x-ray, noncardiogenic 
pulmonary edema and hypoxemia. Further, the severity is graded based on 
the partial pressure of arterial oxygen as a ratio of fraction of inspired 
oxygen. ALI was the term for the mildest form of ARDS in earlier definitions, 
but is still used frequently in animal studies. ALI/ARDS are severe disease 
states that represent a major clinical challenge in intensive care with a 
mortality rate of up to 45% (Maca et al., 2017). A central concept in the 
pathogenesis of ALI/ARDS is dysregulated inflammation. The progression of 
ALI/ARDS comprises deterioration of endothelial and epithelial barriers that 
lead to an increased alveolar-capillary barrier permeability. This results in 
extravasation of plasma into interstitial and alveolar compartments, 
consequently impairing oxygenation and respiratory function. The formation 
of lung edema coincides with accumulation of leukocytes, in particular 
neutrophil granulocytes, which have a decisive function in innate immune 
host defense against invading pathogens. However, besides their protective 
capacity, neutrophils are also known to cause disruption of endothelial 
barriers and to thereby contribute to the pathophysiology of ALI/ARDS 
(Matthay et al., 2012).  
Sepsis is a common cause of acute systemic inflammation and ALI/ARDS 
(Monahan, 2013). Sepsis is according to the latest definition, a “life-
threatening organ dysfunction resulting from dysregulated host responses to 
infection”, and furthermore septic shock is a more severe form of sepsis “in 
which underlying circulatory, cellular and metabolic abnormalities are 
profound enough to substantially increase the risk of mortality” (Cecconi et 
al., 2018). The mortality rate for sepsis is up to 30% and for septic shock it is 
up to 60% (Cecconi et al., 2018). Sepsis can be caused by basically any 
pathogenic microorganism and some of the most common pathogens are 
Gram-positive bacteria such as Staphylococcus aureus, and Gram-negative 
bacteria such as Escherichia coli and Pseudomonas aeruginosa (Cecconi et 
al., 2018). Another pathogen that causes sepsis and septic shock is the Gram-
positive Streptococcus pyogenes, also known as group A Streptococcus 
(GAS). GAS causes common infections such as ‘strep throat’, impetigo, 
scarlet fever and erysipelas, all fairly easily cured with antibiotics. However, 
GAS is also responsible for more severe infections such as pneumonia and 
necrotizing fasciitis that at times lead to the life-threatening septic condition 
streptococcal toxic shock syndrome (STSS) (Stevens and Bryant, 2016).  
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1.2 THE MICROCIRCULATION IN ACUTE INFLAMMATION 
1.2.1 THE VASCULAR WALL AND ENDOTHELIAL CELLS 
The mechanisms of the acute inflammatory response, ultimately leading to 
edema formation, take place in the microcirculation. The microcirculation 
comprises arterioles, capillaries and venules. The vascular wall within the 
microcirculation is built up by a monolayer of endothelial cells that are 
attached to a basement membrane, and to a various extent pericytes and 
smooth muscle cells (Alberts et al., 2002). The endothelium constitutes a 
semipermeable barrier that under normal physiological conditions regulates 
the in- and outflow of fluid, plasma solutes and immune cells between intra- 
and extravascular spaces, making it a decisive factor in maintaining tissue-
fluid homeostasis (Sukriti et al., 2014). The EC barrier has a sifting role, 
allowing water, electrolytes and other small solutes to pass freely through the 
interendothelial junctions, named the paracellular route. Larger molecules 
like albumin can in a controlled manner also pass through the healthy EC 
barrier by vesicular transport with caveolae, named the transcellular route 
(Sukriti et al., 2014).  
Endothelial cells form a single monolayer with cobblestone appearance at the 
innermost layer of the vascular wall. They are attached to one another with 
different types of interendothelial junctions (IEJs). Tight junctions (TJs) are 
IEJs that are highly expressed in arteries and throughout the blood-brain-
barrier and have a stabilizing effect on the EC barrier. They are formed by the 
proteins occludin, claudin and junctional adhesion molecules (JAMs) 
(Sukriti et al., 2014). Adherens junctions (AJs), another type of IEJs, have an 
important role in the regulation of EC permeability to plasma proteins. They 
are formed by homotypic adhesion of the transmembrane protein vascular 
endothelial cadherin (VE-cadherin). TJs and AJs are in close contact with the 
intracellular actin cytoskeleton that is highly involved in inflammatory 
increases in permeability. Besides TJs and AJs, gap junctions also connect 
endothelial cells. They are formed by the protein connexin and mainly seem 
to have a role in direct cell-to-cell transport of solutes and signal molecules 
(Sukriti et al., 2014). On the basolateral side of EC is the basement 
membrane that is composed of collagens, laminins and fibronectin. The 
endothelial cells bind to the basement membrane via cell-matrix focal 
adhesions with integrins, and these junctions are also known to be involved 
in the regulation of vascular permeability (Yuan et al., 2012).  
On the luminal surface of the endothelium is a gel-like layer of glycoproteins, 
proteoglycans and glycosaminoglycans (GAGs) called the glycocalyx. The 
majority of the GAGs (e.g. heparan sulfate and chondroitin sulfate) are 
negatively charged and therefore bind several plasma proteins by 
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electrostatic forces. In normal physiology, the glycocalyx composes a barrier 
that limits vascular permeability, and that maintains an anti-adhesive and 
anti-coagulant layer. In inflammatory disease states, such as sepsis, 
degradation of the glycocalyx may contribute to increased vascular 
permeability (Uchimido et al., 2019).  
1.2.2 BLOOD FLOW IN INFLAMMATION 
The two cardinal signs redness and heat are both a consequence of arteriolar 
vasodilation in the microcirculation. Vasodilation is achieved by vasoactive 
mediators released from residing immune cell, endothelial cells and blood-
borne leukocytes. NO and prostaglandins, such as prostaglandin I2, are 
released from ECs and immune cells, and histamine and bradykinin are 
released from leukocytes. The arteriolar vasodilation leads to an increased 
blood flow that in turn enhances the hydrostatic intravascular pressure, 
partly contributing to an extrusion of fluid and proteins (Pober and Sessa, 
2014) according to Starling’s equilibrium.  
1.2.3 VASCULAR PERMEABILITY IN INFLAMMATION 
Edema formation in inflammation is brought on by leakage of plasma into 
the extravascular space due to an increase in vascular permeability. This 
allows the passage of blood components to the extravascular environment 
and aids in clearing tissue from harmful stimuli. Vascular permeability is 
increased by alterations of the integrity of the EC barrier. Upon stimulation 
with edemagenic agents, reviewed further in the next section, the IEJs of ECs 
open up and cytoskeletal reorganization cause ECs to contract, resulting in 
formation of interendothelial gaps. The cytoskeletal change induced in 
inflamed endothelium is known as stress fiber formation, a typical 
appearance caused by polymerization of actin and myosin filaments (Sukriti 
et al., 2014). Binding of a permeability-increasing mediator to an EC induces 
actomyosin contractile activity via myosin light-chain (MLC). MLC is 
phosphorylated by myosin light-chain kinase (MLCK) that can be activated 
by multiple signals, including increased cytosolic Ca2+, protein kinase C and 
tyrosine kinases. Furthermore, Rho-associated kinase (ROCK) is activated by 
RhoA, a small GTPase, and contributes to increased activity of MLC (Rigor et 
al., 2013). Besides contraction of ECs, there is also a disassembly of IEJs 
following stimulation with inflammatory mediators. Of the IEJs, especially 
AJs are suggested to be involved in increases in permeability due to 
phosphorylation of VE-cadherin (Dejana and Vestweber, 2013). In summary, 
both contraction of cells due to actomyosin activation and retraction of cells 
caused by disassembly of IEJs, are important mechanisms of the formation 
of interendothelial gaps. 
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1.2.4 MEDIATORS OF VASCULAR HYPERPERMEABILITY 
There are several known inflammatory mediators that increase vascular 
permeability via direct effects on EC. Thrombin, histamine, bradykinin, 
cysteinyl leukotrienes, vascular endothelial growth factor (VEGF) and TNF 
are all known to destabilize the endothelial barrier (Mehta et al., 2014, Duah 
et al., 2013). Our work centered around the role of bradykinin in acute 
inflammation. 
1.2.4.1 Bradykinin 
Bradykinin (BK) is a short-lived nonapeptide (9 amino acids) that is known 
to increase endothelial permeability. BK is formed upon activation of the 
kallikrein-kinin system (KKS), an inflammatory response mechanism 
constituted by the plasma proteins prekallikrein (PK), factor XII (FXII) and 
high molecular weight kininogen (HK) (Schmaier, 2016). Activation of FXII 
in turn activates PK that subsequently cleaves HK that result in BK 
formation. Besides FXII-dependent activation of KKS, PK can also be 
activated by prolylcarboxypeptidase (PRCP) located on ECs (Shariat-Madar 
et al., 2002), and neutrophil-derived proteases have been found to directly 
liberate BK from kininogens (Imamura et al., 2002, Stuardo et al., 2004, 
Kahn et al., 2009). Besides HK, there is also low molecular weight kininogen 
(LK) and both have the common domain 4 that is the part that forms BK 
upon proteolytic cleavage (Schmaier, 2016). The plasma concentration of HK 
is about 100 µg/ml and it binds to ECs, neutrophils and platelets via heparan 
sulfate, urokinase receptor (uPAR) and others. Furthermore, HK binds M 
protein, a membrane-bound virulence factor on group A Streptococcus (Ben 
Nasr et al., 1995). The main function of HK is thought to be liberation of BK, 
which in turn induces EC barrier disruption by binding the G-protein-
coupled bradykinin B1 and B2 receptors on ECs. Bradykinin B2 receptor is 
constitutively expressed and bradykinin B1 receptor is upregulated during 
inflammation (Schmaier, 2016). BK-induced increase in endothelial 
permeability has been suggested to involve both ROCK and MLC signaling, 
leading to cytoskeletal stress fiber formation (Ma et al., 2012), as well as 
disassembly of VE-cadherin (Orsenigo et al., 2012).  
1.2.4.2 Others 
Leukotrienes (LTs) and prostaglandins (PGs) are lipid mediators with 
numerous roles in inflammatory processes, and they are formed by 
enzymatic processing of arachidonic acid. Whereas PGs mainly have 
functions regulating vasodilation, coagulation and induction of fever, and are 
formed by cyclooxygenases (COX) by several cell types (Ricciotti and 
FitzGerald, 2011), leukotrienes are more involved in immune cell recruitment 
and alterations in EC permeability, and are formed by lipoxygenases (LOX) 
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mainly in immune cells. Leukotriene B4 (LTB4) is a potent chemoattractant 
for neutrophils and induces neutrophil activation and degranulation. LTC4, 
LTD4 and LTE4, called the cysteinyl leukotrienes, have, amongst other effects, 
a known capacity to induce vascular hyperpermeability (Busse, 1998).  
Thrombin is a serine protease formed from prothrombin that has a key role 
in both primary hemostasis by activating platelets as well as secondary 
hemostasis by mediating fibrin formation (Posma et al., 2016). Furthermore, 
thrombin causes EC barrier disruption by binding protease-activated 
receptor 1 (PAR-1) on ECs, leading to RhoA and MLCK activation (Sukriti et 
al., 2014).  
Histamine is a hormone and an inflammatory mediator predominantly 
originating from mast cells and basophil granulocytes. Upon pathogenic or 
allergenic antigen binding to membrane-bound IgE antibodies, histamine is 
released and binds histamine H1 receptor on ECs, which induces EC barrier 
disruption by increasing intracellular Ca2+, MLCK activation and also by 
phosphorylation of AJs and TJs (Sukriti et al., 2014).  
As compared to the previously mentioned mediators, TNF is known to 
destabilize the EC barrier in a more delayed fashion by the induction of 
nuclear factor kappa B (NF-κB) transcription, increased cytokine production 
and upregulation of leukocyte adhesion molecules such intercellular 
adhesion molecule 1 (ICAM1) (Sukriti et al., 2014). 
 
1.3 LEUKOCYTES 
Leukocytes are the main defenders of the human body and they appear in 
many different forms. They are divided into polymorphonuclear (PMNs) and 
mononuclear leukocytes. The PMNs have irregularly shaped nuclei and they 
are all granulocytes since they contain cytoplasmic granules. The PMNs are 
further divided into neutrophils, eosinophils and basophils. Neutrophil 
granulocytes are the most abundant leukocytes, constituting 50-70% of 
leukocytes, and will be further reviewed below. Neutrophils are often referred 
to as PMNs, since they normally constitute about 95% of the PMNs. 
Eosinophil granulocytes are involved in the host response against parasitic 
infections and also, like basophil granulocytes, in allergic inflammation. The 
mononuclear leukocytes are the monocytes and the lymphocytes (such as B- 
and T-cells). Furthermore, there are tissue-resident leukocytes such as 
macrophages, dendritic cells and mast cells (Boron and Boulpaep, 2012).  
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1.3.1 LEUKOCYTE RECRUITMENT 
Extravasation of leukocytes, which is mainly restricted to the postcapillary 
venules, has been studied for almost 200 years (first described by Dutrochet 
in 1824). The mechanisms regulating recruitment of leukocytes during acute 
inflammation is known as the leukocyte adhesion cascade and is divided into 
a series of steps; margination, capture, rolling, slow rolling, arrest, adhesion 
strengthening and spreading, intravascular crawling, and paracellular and 
transcellular migration (Ley et al., 2007). 
Initially, smooth muscle cell relaxation and vasodilation enables increased 
contact between leukocytes and endothelium, termed margination. When in 
contact with EC, leukocyte rolling is mediated predominantly by the selectins 
(L-, P- and E-selectin) interacting with P-selectin glycoprotein ligand 1 
(PSGL1) and other as yet unknown ligands. L-selectin is expressed on 
leukocytes and P- and E-selectins are expressed on activated EC. P-selectin is 
also upregulated on activated platelets. Slow rolling occurs as a next step due 
to interaction of PSGL1 and β2 integrins on leukocytes with E-selectin and 
ICAM1 on activated ECs. Two important β2 integrins on PMNs are 
CD11a/CD18 (lymphocyte function-associated antigen 1, or LFA1) and 
CD11b/CD18 (macrophage receptor 1, or MAC1) (Ley et al., 2007). During 
slow rolling, leukocytes are activated by chemotactic mediators such as 
interleukin-8 (IL-8) and LTB4 presented on EC. Activation of leukocytes 
results in a rapid activation of integrins (conformational change by inside-out 
signaling) that then bind ICAM1 and vascular cell adhesion molecule 1 
(VCAM1) on EC. This leads to arrest and firm adhesion of leukocytes (Ley et 
al., 2007). β2 integrins are essential for adhesion of neutrophils, as adhesion 
as well as subsequent transmigration is abolished upon blocking the function 
of CD18 (Arfors et al., 1987). Before they migrate through the vessel wall, 
leukocytes crawl on the endothelium to find a suitable site for extravasation, 
and intraluminal crawling has been shown to be dependent on MAC1 and 
ICAM1 interaction (Phillipson et al., 2006). Two distinct pathways for 
leukocytes through the endothelium have been found: a paracellular route 
where leukocytes migrate through interendothelial junctions, and a 
transcellular route where they pass through the body of the ECs (Ley et al., 
2007).   
1.3.2 NEUTROPHIL GRANULOCYTES 
Neutrophils are the main effectors of acute inflammation and they are first 
on site following tissue injury or infection. In homeostasis, they are 
continuously released from bone marrow and circulate the blood for a short 
period of time before they end up in for example liver or spleen and go into 
apoptosis (Kubes, 2018). During inflammation, the release of neutrophils 
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from bone marrow is increased up to ten times. In humans, neutrophils 
constitute 50-70% of leukocytes in blood, in difference to mice where they 
make up 10-25%. Neutrophils have a segmented nucleus and contain 
secretory vesicles and three types of cytoplasmic granules. The granules are 
formed in a specific order during neutrophil maturation and are traditionally 
divided into azurophilic (primary), specific (secondary) and gelatinase 
(tertiary) granules (Cowland and Borregaard, 2016). The granules and 
secretory vesicles together contain several hundreds of proteins. 
For the eradication of pathogens and noxious stimuli, neutrophils can apply 
both intra- and extracellular methods. Intracellular microbial killing 
following phagocytosis is performed with the use of reactive oxygen species 
(ROS) and granule-derived bactericidal proteins in the phagolysosome 
(Kolaczkowska and Kubes, 2013). Reactive oxygen species such as superoxide 
anion (O2-), hydrogen peroxide (H2O2), hydroxyl anions (OH-), hydroxyl 
radicals (OH) and hypochlorous acid (HOCl) are produced by nicotinamide 
adenine dinucleotidephosphate (NADPH) oxidase. ROS production in 
inflammation is to a considerable degree caused by neutrophils, and besides 
actions in the phagolysosome, ROS can also be released extracellularly, called 
a respiratory burst (Meegan et al., 2017).  
Degranulation and release of granule content is another mechanism of 
neutrophils to extracellularly combat pathogens. Degranulation is mediated 
following activation of neutrophils by for example IL-8, LTB4 or bacterial 
components that via membrane-bound receptors mediate intracellular 
signaling involving increase in cytosolic Ca2+ and actin cytoskeletal 
remodeling. This results in granule exocytosis with release of soluble 
granule-derived proteins and presentation of membrane bound granule-
specific receptors on the neutrophil surface (Lacy, 2006). It is generally 
considered that the secretory vesicles are the first to be released, followed in 
an orderly fashion by gelatinase, specific and finally azurophilic granules. In 
table 1, a selection of the most abundant granule proteins in their respective 
granule subset is shown. 
The secretory vesicles are considered to be formed by endocytosis since they 
contain plasma proteins such as albumin and α-1-antitrypsin. Further, they 
house membrane bound receptors towards pathogens and factors of the 
complement system, as well as β2 integrins (Rorvig et al., 2013). The contents 
of the gelatinase and the specific granules somewhat overlap. Matrix 
metalloproteinase-9 (MMP9) that cleaves gelatin and collagen is found in 
gelatinase granules. Cathelicidin antimicrobial peptide (CAMP), which is 
cleaved into LL-37 upon release, is located in both types of granules and have 
antimicrobial effects. Neutrophil gelatinase-associated lipocalin (NGAL) is 
found in specific granules and has, amongst other, bacteriostatic effects. The 
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azurophil granules contain the serine proteases neutrophil elastase (NE), 
proteinase 3 (P3), cathepsin G (CG) and the enzymatically inactive heparin-
binding protein (HBP/azurocidin), together called the serprocidins. They 
have various antimicrobial effects and are also involved in recruitment of 
immune cells (Cassatella et al., 2019). Furthermore, they are known to 
increase endothelial permeability. HBP has also been localized in secretory 
vesicles of neutrophils (Tapper et al., 2002). Also, in the azurophil granules 
myeoloperoxidase (MPO), the defensins (human neutrophil peptides 1-3) 
and bactericidal permeability-increasing protein (BPI), all with antimicrobial 
effects, are found (Cassatella et al., 2019). 
Beyond respiratory burst of ROS and degranulation of granule proteins, 
neutrophils can undergo neutrophil extracellular trap (NET) formation, 
where the neutrophil extrudes a web of DNA, histones, granule proteins and 
cytoplasmic proteins, which has the ability to trap and kill pathogens 
(Kolaczkowska and Kubes, 2013). NETs were first discovered in 2004 as a 
novel pathogen-killing mechanism (Brinkmann et al., 2004), and since then 
both pathogens and host factors have been found to induce NET formation.   
 
Table 1. Neutrophil granule subsets and most abundant proteins in each type of 
granules and secretory vesicles.A  
 
Azurophil 
granules 
Specific 
granules 
Gelatinase 
granules Secretory vesicles 
Myeloperoxidase (MPO) 
Cathepsin G (CG) 
Proteinase 
3/Myeloblastin (P3) 
Neutrophil elastase (NE) 
Heparin-binding protein 
(HBP)/Azurocidin 
Neutrophil serine 
protease 4 (NSP4) 
Bactericidal 
permeability-increasing 
protein (BPI) 
Defensins (HNPs) 
Lysosomal proteases 
Lactoferrin 
Collagenase 
Lysozyme 
Neutrophil 
gelatinase-associated 
lipocalin (NGAL) 
Pentraxin 3 
Haptoglobin 
Cathelicidin 
antimicrobial peptide 
(CAMP)/LL-37 
Olfactomedin-4 
Complement 3a 
receptor 
Gelatinase B/Matrix 
metalloproteinase-9 
(MMP9) 
Ficolin-1 
Cathelicidin 
antimicrobial peptide 
(CAMP)/LL-37 
 
β2 integrins 
Heparin-binding 
protein 
(HBP)/Azurocidin 
Complement receptor 1 
Formyl peptide 
receptor (FPR) 
Plasma proteins 
Toll-like receptors 
(TLRs) 
 
A Based on previous work (Rorvig et al., 2013, Cowland and Borregaard, 2016, Cassatella et al., 2019).  
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1.4 NEUTROPHIL-MEDIATED VASCULAR LEAKAGE 
In acute inflammation, when neutrophils adhere to activated endothelium of 
a vessel wall in the microcirculation, endothelial permeability increases and 
plasma starts to leak out to the interstitial space. That neutrophils induce 
plasma leakage has been known for a long time (Wedmore and Williams, 
1981). Following these observations it was found that adhesion of neutrophils 
to EC is mediated via β2 integrins, and that mere adhesion, and not 
necessarily extravasation of neutrophils, is enough to induce plasma leakage 
(Arfors et al., 1987, Gautam et al., 2000).  
There are several mechanisms suggested to be involved in neutrophil-
induced microvascular leakage. Upon binding of β2 integrins to ICAM1, 
intracellular signaling in EC ultimately result in interendothelial gap 
formation. MLC phosphorylation by MLCK, as well as RhoA and ROCK 
activation, is involved in neutrophil-induced EC stress fiber and 
interendothelial gap formation (Yuan et al., 2002, Breslin and Yuan, 2004). 
Furthermore, tyrosine phosphorylation of focal adhesion kinase (FAK) was 
also shown in EC upon neutrophil stimulation (Guo et al., 2005). Neutrophils 
also have known disruptive effects on the interendothelial junctions by 
affecting VE-cadherin (Tinsley et al., 2002, Wessel et al., 2014).   
Following stimulation with for example LTB4 or complement factor 5a (C5a), 
or upon engagement of β2 integrins, neutrophils are activated resulting in 
release of mediators, such as granule proteins, with effects on the EC barrier. 
This can occur either as a consequence of neutrophil adhesion, whereby the 
endothelium is affected both via ICAM1-signaling as well as via paracrine 
mechanisms, or it can occur in non-adherent neutrophils. Supernatants from 
neutrophils stimulated with LTB4 or C5a have been found to contain granule 
proteins and to induce EC hyperpermeability (Breslin and Yuan, 2004, Di 
Gennaro et al., 2009). In a study by Gautam and colleagues, antibody cross-
linking of β2 integrins, as a way of mimicking neutrophil adhesion to EC, 
resulted in outside-in signaling and release of cationic neutrophil-derived 
proteins that induced EC stress fiber formation and plasma leakage (Gautam 
et al., 2000). In line with this, M protein, a virulence factor of GAS, was 
shown to induce neutrophil degranulation of all subsets of granules via 
binding of β2 integrins (Soehnlein et al., 2008a).  
Upon activation via soluble mediators or receptor engagement, neutrophils 
release granule proteins, ROS as well as NETs, and they have all been found 
to contribute to EC barrier disruption. Granule proteins such as the serine 
proteases NE, CG and P3 are released from activated neutrophils and 
increase endothelial permeability. They cleave AJs and components of the 
extracellular matrix (Sharony et al., 2010), and also cleave receptors, thereby 
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mediating intracellular signaling promoting cytoskeletal rearrangement 
(Korkmaz et al., 2010). HBP/azurocidin, which is enzymatically inactive, has 
also been shown to increase permeability (Gautam et al., 2001, Herwald et 
al., 2004, Bentzer et al., 2016). The granule protein myeloperoxidase (MPO) 
is abundantly expressed in neutrophils and facilitates formation of 
microbicidal reactive oxidants. MPO catalyzes the formation of hypohalous 
acids, such as hypochlorous acid, that has damaging effects on EC and 
increase EC permeability (Patterson et al., 2014). Eosinophil peroxidase 
(EPO) and eosinophil cationic protein (ECP), granule proteins mainly 
considered to originate from eosinophil granulocytes but that are also found 
in neutrophils, are other mediators that increase vascular permeability 
(Minnicozzi et al., 1994). Inhibition of ROS production or treatment with 
antioxidants decreased neutrophil-induced inflammation (Zhu and He, 
2006, Boueiz and Hassoun, 2009), and both effects on IEJs and effects on 
intracellular signaling and cytoskeletal reorganization has been proposed 
(Mittal et al., 2014).  
Data over the last decade has indicated that NETs can affect endothelial 
permeability (Ma et al., 2019). NETs have destructive effects on ECs in vitro 
(Saffarzadeh et al., 2012), and were suggested to cause plasma leakage in 
vivo (Caudrillier et al., 2012). NETs are constituted by nuclear, granular and 
cytosplasmic proteins (Urban et al., 2009). Nuclear-derived histones are 
found in NETs and have been shown to cause endothelial and epithelial 
disruption (Abrams et al., 2013, Saffarzadeh et al., 2012, Wildhagen et al., 
2014). Furthermore, the cytoplasmic calcium-binding proteins S100A8, A9 
and A12 are also found in NETs and they all increase endothelial 
permeability (Wang et al., 2014, Wittkowski et al., 2007).  
Transendothelial migration of neutrophils and increased vascular 
permeability has previously been considered as coupled events whereby 
neutrophils create holes in the EC barrier as they extravasate that lead to 
leakage of plasma. As of today, this concept is revised following several 
studies showing spatial and temporal uncoupling of these events (for a 
review, see (He, 2010)). In addition, it was recently shown that regulation of 
leukocyte extravasation and vascular permeability differed in terms of 
tyrosine phosphorylation of VE-cadherin (Wessel et al., 2014). As a 
mechanistic basis for how the EC barrier remains its integrity during 
neutrophil diapedesis, Heemskerk and colleagues found that EC form tight 
pores involving F-actin that allows transmigration without leakage of plasma 
(Heemskerk et al., 2016).  
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1.4.1 NEUTROPHILS IN ACUTE SYSTEMIC INFLAMMATION AND 
LUNG INJURY 
Neutrophil recruitment and activation are considered key events in the 
development of ALI and ARDS, feared complications of either direct 
pulmonary insult or of indirect acute systemic inflammatory conditions 
(Grommes and Soehnlein, 2011, Williams and Chambers, 2014, Rebetz et al., 
2018). Neutrophils have been called double-edged swords, due to that they 
possess both important protective antimicrobial effects as well as tissue-
destructive capacity. Sepsis and septic shock can lead to the development of 
ARDS, and in the pathogenesis of sepsis and septic shock, neutrophils play a 
major role (Sonego et al., 2016, Stiel et al., 2018). In patients with ARDS, 
neutrophil count in broncho-alveolar lavage (BAL) fluid was found to 
correlate with ARDS severity (Aggarwal et al., 2000). Furthermore, 
neutrophil depletion in different animal models of ALI has been found to 
improve pulmonary microcirculation and to prevent plasma leakage (Park et 
al., 2019, Looney et al., 2006). In support of a role for neutrophil-derived 
proteins in ALI/ARDS, intravenous administration of streptococcal M 
protein was found to cause ALI by inducing neutrophil degranulation 
(Soehnlein et al., 2008a). Also, α-defensins were found to disrupt the 
capillary-epithelial barrier and cause lung injury in mice (Bdeir et al., 2010), 
and neutrophil elastase has been found to take part in ALI pathogenesis 
(Kawabata et al., 2002). The dysregulated activation of neutrophils during 
septic shock, including release of NETs, also contributes to activation of 
coagulation that can develop into septic shock-induced coagulopathy. 
Immunothrombosis is a mechanism of intravascular immunity that allows 
for capture of microorganisms in microthrombi and that involves NETs. 
However, uncontrolled activation of immunothrombosis, suggested to be 
mediated by neutrophils, can lead to disseminated intravascular coagulation 
(DIC), a feared complication in septic shock (Stiel et al., 2018). 
 
1.5 PLATELETS IN NEUTROPHILIC INFLAMMATION 
Platelets are anuclear cell fragments derived from megakaryocytes that have 
important functions in restricting bleeding from vessels following injury – a 
process termed hemostasis and that also include coagulation factors. 
Platelets and coagulation factors also take part in thrombosis, the 
pathological formation of blood clots in the vessel lumen. Besides their role 
in hemostasis and thrombosis, platelets are also highly involved in 
inflammation and host response to infections (Deppermann and Kubes, 
2018). Platelets adhere to endothelium during inflammation and are 
suggested to be important in the progression of ALI (Zarbock and Ley, 
2009). When activated, platelets and neutrophils form platelet-neutrophil 
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complexes that contribute to neutrophil-mediated lung edema. Inhibition of 
platelet-neutrophil complex formation, and also depletion of either 
neutrophils or platelets, has been found to reduce lung edema in ALI 
(Zarbock et al., 2006, Looney et al., 2009). Furthermore, in models of sepsis 
and ALI, neutrophil activation resulting in NET formation was found to be 
dependent on platelet-neutrophil interactions (McDonald et al., 2012, 
Caudrillier et al., 2012).  
Both paracrine and receptor-mediated mechanisms for platelet-induced 
neutrophil activation have been found. Neutrophils are activated upon 
binding of P-selectin to PSGL-1 on neutrophils, as well as by interaction of 
the membrane glycoprotein GPIbα or platelet integrins with β2 integrins on 
neutrophils (Lisman, 2018). Also, platelet-mediated NET formation was 
shown to be induced via HMGB1 presented on the surface of platelets 
(Maugeri et al., 2014). Furthermore, the chemokines CXCL7 and CCL5-
CXCL4 heteromers displayed paracrine effects on neutrophils following 
release from activated platelets, thus contributing to ALI in mice (Bdeir et al., 
2017, Grommes et al., 2012). Another paracrine mediator of platelet-induced 
neutrophil activation is serotonin that recently was found to induce 
neutrophil degranulation and to take part in myocardial ischemia-
reperfusion injury (Mauler et al., 2019).  
Platelets contain two types of granules, α-granules and dense granules, which 
house more than 300 membrane-bound and soluble mediators that can be 
mobilized upon platelet activation (Golebiewska and Poole, 2015). Inorganic 
polyphosphates (polyP) are linear polymers of inorganic phosphate residues 
that are located in dense granules of platelets (Ruiz et al., 2004). PolyP is 
furthermore found in granules of mast cells and basophil granulocytes 
(Moreno-Sanchez et al., 2012). PolyP was shown to be released from 
activated platelets and to stimulate both coagulation and inflammation 
(Morrissey and Smith, 2015), and also to mediate bradykinin formation and 
plasma leakage by activating FXII (Muller et al., 2009). Furthermore, polyP 
was found to increase EC permeability, enhance adhesion molecule 
expression on EC and to induce neutrophil recruitment (Bae et al., 2012, 
Hassanian et al., 2015). Besides residing in mammalian cells, inorganic 
polyphosphates are also found in prokaryotes and can differ in length from 
only a few phosphate residues to up to thousands. Polymer length has been 
found to affect the capacity of polyP to induce coagulation as well as its 
proinflammatory potential (Morrissey and Smith, 2015, Brown and 
Kornberg, 2004). 
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1.6 RESOLUTION OF INFLAMMATION 
Following an inflammatory response, the immune system initiates a 
resolving phase aimed at restoring tissue function. After neutrophils have 
arrived to a site of injury or infection, they actuate a second swell of immune 
cells by recruiting inflammatory monocytes that aid in neutralizing the cause 
for inflammation (Soehnlein et al., 2008b). When this task is fulfilled, 
neutrophils become apoptotic and release mediators that signal to abort 
further infiltration of neutrophils (Ortega-Gomez et al., 2013, Soehnlein and 
Lindbom, 2010). Chemokine depletion by enzymatic cleavage or 
sequestration terminates the recruitment of neutrophils and monocytes, and 
apoptotic neutrophils release annexin A1, that promotes further apoptosis, 
and lactoferrin, that has anti-inflammatory properties (Li et al., 2012, 
Ortega-Gomez et al., 2013). Pro-inflammatory macrophages start engulfing 
apoptotic neutrophils, a term called efferocytosis, and at the same time 
switch their phenotype and become pro-resolving. They stop producing pro-
inflammatory cytokines and eicosanoids such as TNF and LTB4, and instead 
begin to release interleukin 10 (IL-10) and transforming growth factor β 
(TGF-β), two cytokines with anti-inflammatory effects. Following this switch, 
the resolution-phase macrophages also increase their ability to present 
antigen and stimulate recruitment of B- and T-cells (Ortega-Gomez et al., 
2013).  
Eicosanoids, lipid mediators derived from arachidonic acid (AA) or other 
polyunsaturated fatty acids (PUFAs), play a central role in both initiation and 
resolution of inflammation. Prostaglandins and leukotrienes, derived from 
AA with cyclooxygenases (COX) and lipoxygenases (LOX), respectively, 
induce vasodilation and increase in vascular permeability, and promote 
neutrophil activation and recruitment during the initiation of inflammation 
(Serhan et al., 2008). Whereas 5-LOX mainly converts AA into pro-
inflammatory leukotrienes, 12-LOX and 15-LOX instead can convert AA into 
lipoxins that are mediators with both anti-inflammatory and pro-resolving 
activities. Furthermore, LOX can convert ω3-PUFAs into resolvins and 
protectins that have similar activities as lipoxins. The difference between 
anti-inflammatory and pro-resolving activities is that pro-resolution 
mediators are not immunosuppressive, but stimulate resolution by 
enhancing recruitment of monocytes, promoting macrophages to 
phagocytose apoptotic cells and microbes, as well as by inducing expression 
of antimicrobial mediators (Serhan et al., 2008).   
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1.7 MODULATION OF NEUTROPHILIC INFLAMMATION  
Since inflammation is a significant factor in the pathogenesis of several 
disease states, ways to control inflammation have been studied extensively. 
As of today, there are numerous anti-inflammatory agents targeting different 
pathways that are used to inhibit the inflammatory response. However, new 
approaches are still sought after due to limited and/or adverse effects. An 
intricate challenge is that on the one hand there is a need to find better ways 
to control the inflammatory host response, and on the other not to hamper 
host defense. In terms of infectious disease, strategies that can enhance host 
defense are suggested to improve treatment. For example, patients afflicted 
with sepsis that survive the hyperinflammatory cytokine storm in some cases 
develop immunoparalysis with impaired neutrophil function that is 
associated with increased mortality (Tisoncik et al., 2012). Below, examples 
of various treatment strategies are reviewed.  
1.7.1 INHIBITION OF MEDIATOR PRODUCTION 
Reducing the production of inflammatory mediators can inhibit the 
inflammatory response. Glucocorticoids mainly exercise their anti-
inflammatory effects by binding intracellular glucocorticoid receptors that in 
turn hinder gene expression of pro-inflammatory mediators such as 
cytokines and cyclooxygenases via inhibition of the transcription factors NF-
κB and activator protein-1 (AP-1). Furthermore, glucocorticoids mediate 
non-genomic actions by decreasing the release of AA (Ramamoorthy and 
Cidlowski, 2016). In all, glucocorticoids broadly target inflammation at the 
base of the signaling pathways, generating inhibition of the increase of pro-
inflammatory cytokines, prostaglandins as well as the recruitment of 
immune cells. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit 
inflammation by targeting COX-1 and/or COX-2, thus hindering the 
formation of prostaglandins that are responsible for inducing inflammatory 
vasodilation and sensitization of nociceptors. Furthermore, NSAIDs also 
have an antipyretic effect (Diaz-Gonzalez and Sanchez-Madrid, 2015).  
Another group of drugs with anti-inflammatory effects are disease-modifying 
antirheumatic drugs (DMARDs), which are mainly used for their 
immunosuppressive effects. An example of these is the synthetic DMARD 
methotrexate that inhibits the immune system on DNA level (Brown et al., 
2016). A downside with treatments that inhibit production of inflammatory 
mediators is that it increases the risk of disseminating infection and that it 
impairs resolution of inflammation (Voiriot et al., 2019).  
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1.7.2 INHIBITION OF NEUTROPHIL FUNCTION 
Recruitment of leukocytes is a hallmark of the inflammatory response, taking 
place in the postcapillary venules by the interaction of several cell adhesion 
molecules (CAMs) expressed on leukocytes and EC. Due to its crucial role in 
inflammation, targeting the leukocyte adhesion cascade has therefore been 
suggested as a promising approach to antagonize inflammation. Inhibitors of 
selectins, β2 integrins (CD11/CD18) and ICAM have shown promise in 
preclinicial studies, but results from clinical trials evaluating treatment of 
inflammatory disease states such as ischemia-reperfusion and myocardial 
and cerebral ischemic injury have been inconsistent (Ulbrich et al., 2003). 
The fact that inhibiting CD18-mediated adhesion with blocking antibodies 
mimics the genetic disorder leukocyte adhesion deficiency (LAD), 
characterized by recurrent bacterial infections due to impaired neutrophil 
recruitment, might indicate potential adverse effects of such treatment 
strategies.  
Neutrophils are highly involved in ARDS pathogenesis and a multitude of 
different neutrophil-associated targets have been tested in preclinical studies 
of acute lung injury. To name a few, antagonists against TLRs, cytokines and 
chemokines, inhibition of the granule proteins neutrophil elastase and 
different matrix metalloproteinases, deoxyribonuclease I (DNAse I) 
treatment targeting NETs and treatment with antioxidants against ROS have 
been tested (Potey et al., 2019). 
Bradykinin formation via activation of the KKS is known to increase vascular 
permeability, and neutrophil-derived proteases have previously been shown 
to induce BK formation (Imamura et al., 2002, Stuardo et al., 2004, Kahn et 
al., 2009). Hereditary angioedema is a disease in which mutations in the 
gene encoding C1 esterase inhibitor result in exaggerated bradykinin 
formation. This leads to attacks of cutanenous and mucosal edema that can 
be treated with a bradykinin B2 receptor antagonist (HOE 140/icatibant) or a 
plasma kallikrein inhibitor (DX88/ecallantide) (Longhurst and Bork, 2019). 
Heparin is a strongly negatively charged polysaccharide with anticoagulant 
properties, which alongside low molecular weight derivatives is extensively 
used in clinical practice to treat and prevent thrombosis. Heparin also 
possesses documented anti-inflammatory properties such as inhibition of 
different aspects of neutrophil activation (Mulloy et al., 2016). The anti-
inflammatory activities have been found to function independent of the 
anticoagulant, which are mainly confined to a specific pentasaccharide 
sequence that potentiates the effect of antithrombin III. Therefore, chemical 
modifications of heparin have been made that reduce the anticoagulant 
quality while retaining the anti-inflammatory. Such low anticoagulant 
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heparin derivatives have been found to attenuate acute inflammation by 
inhibiting neutrophil-derived proteins (Rao et al., 2010, Wildhagen et al., 
2014). 
1.7.3 ENHANCEMENT OF HOST DEFENSE 
Due to a suggested increase in the prevalence of immunosuppression, 
explained by expanded use of immunosuppressive drugs and increased life 
expectancy (Harpaz et al., 2016), as well as the increase in antibiotic 
resistance, there is a need for finding new ways to treat infectious disease. An 
optimal therapeutic against inflammation caused by infection with a 
pathogen would enhance the host defense whilst controlling the neutrophil-
associated tissue-damaging inflammatory response. 
A promising target is inositol hexakisphosphate kinase 1 (IP6K1), an enzyme 
involved in modulating neutrophil functions such as phagocytosis and ROS 
production, and that also regulates the production of polyP in platelets. It 
was recently shown that mice deficient in IP6K1 subjected to bacterial 
pneumonia had enhanced bacterial killing whilst having reduced neutrophil 
infiltration and lung damage (Hou et al., 2018). This study also found that 
platelet polyP had a major role in inducing neutrophil activation with 
subsequent pulmonary inflammation.   
Another potential therapeutic strategy with both anti-inflammatory and 
immune modulating effects is treatment with short-chain fatty acids 
(SCFAs). The SCFAs butyrate, propionate and acetate are shown to be 
involved in regulating inflammation (Li et al., 2018). In several studies, 
sodium butyrate and its analogue phenylbutyrate (PBA) were found to 
attenuate inflammatory responses (Ni et al., 2010, Vieira et al., 2012, 
Venkatraman et al., 2003, Liang et al., 2013, Ono et al., 2017, Kim et al., 
2013). Furthermore, sodium butyrate and PBA has been shown to induce 
expression of antimicrobial peptides (AMPs) (Schauber et al., 2004, 
Steinmann et al., 2009, Mily et al., 2013, Sarker et al., 2011). In humans, the 
AMPs are the α- and the β-defensins and the cathelicidin LL-37. They are 
expressed by immune cells and epithelial cells, and have antimicrobial as well 
as immune-modulating and pro-resolving effects (Steinstraesser et al., 2011).
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 AIMS 2.
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The overall aim of this thesis was to investigate the mechanisms of 
neutrophil-induced vascular hyperpermeability in acute inflammation, with 
an attempt to find novel treatment strategies. 
Specifically, the aim of each study was as follows: 
 
Study I: Investigate the role of the kallikrein-kinin system in neutrophil-
evoked endothelial barrier disruption. 
 
Study II: Investigate the effect and mode of action of heparinoid sevuparin 
on neutrophil-induced plasma leakage in acute systemic inflammation  
Study III: Investigate the role of platelet-derived polyphosphates in 
neutrophilic inflammation. 
Study IV: Investigate the effect of phenylbutyrate treatment on the 
inflammatory response and the role of cathelicidin in murine pulmonary 
inflammation.  
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 EXPERIMENTAL 3.
PROCEDURES 
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For detailed descriptions, see methods sections in paper I-IV.  
 
3.1 ETHICAL STATEMENT 
All animal experiments were performed in accordance with ethical 
applications approved by Stockholm Ethics Committee for Animal 
Experiments. Collection of blood from healthy donors was performed in 
accordance with ethical application approved by the Regional Ethics Review 
Board in Stockholm. 
 
3.2 IN VIVO METHODOLOGY 
In the research field of immunology and inflammation, animal models are 
widely used to increase our understanding of the human immune system. 
Although animal models have many limitations and do not fully reflect 
human diseases, their use has overall been invaluable for increasing our 
knowledge in human functions in health and disease, and also for the 
development of novel treatments. The immune system, especially the innate 
immune system that is the focus of this thesis, is highly conserved 
throughout evolution and has enabled the development of a multitude of 
animal models of inflammation. Inflammation research has employed 
animal models for almost a century, resulting in considerable advances in 
understanding and treatment of human inflammatory disease (Webb, 2014). 
When utilizing animal models there are numerous factors that can influence 
the results. With regards to models of inflammation and neutrophils, some 
examples are; the gender of the animals (Kay et al., 2015), the time of day for 
experiment (Adrover et al., 2019) and the method of anesthesia (Cruz et al., 
2017). 
Two different mouse strains were used throughout this thesis work.  In paper 
I and IV, female C57bl/6 were utilized, with the knockout mice strains 
BdkB2-/- and F12-/- in paper I being on a C57bl/6 background. In paper II and 
III, male Balb/c mice were used. In all cases, wild type mice were from 
Harlan. C57bl/6 and Balb/c are both inbred strains, meaning that the 
genotype is near identical in between individual animals. These strains were 
chosen since they are both commonly used for research on inflammation. 
The use of inbred strains is favorable when high reproducibility is wanted, 
the downside being that results might not in the same manner translate into 
the genetically diverse human setting.  
Below, the in vivo models utilized for this thesis work will be reviewed.  
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3.2.1 INTRAVITAL MICROSCOPY OF HAMSTER CHEEK POUCH 
Intravital microscopy (IVM) is a suitable method when real-time high-
resolution visualization of physiological and pathophysiological processes is 
wanted, and is the only method that allows detailed spatiotemporal 
assessment of the inflammatory process at the microvascular level. In a 
historical context, IVM has played a crucial role in our understanding of 
immunology and physiology (Secklehner et al., 2017). IVM can be performed 
on a multitude of different tissues and in different species. For example, 
cremaster muscle, skin, liver, lung and mesentery can all be studied in mice 
with IVM. The cheek pouch of hamsters is another example, well suited for 
detailing plasma extravasation, and is the one that was used in paper I in this 
thesis.  
IVM of the hamster cheek pouch is a well-established method to study the 
microcirculation in vivo. It allows for detailed assessment of leukocyte 
recruitment and alterations in vascular permeability in real-time (Raud and 
Lindbom, 1994). Briefly, in an anaesthetized hamster, the cheek pouch is 
turned inside out and pinned down on to a transparent plate. The 
microcirculation within the pouch can then be observed with light 
microscopy. To study leukocyte recruitment, chemoattractants can be 
administered in various ways such as topical application onto tissue or by 
intravenous injection. To study the alteration in vascular permeability that 
occurs subsequent to leukocyte adhesion, a fluorescent plasma marker is 
administered intravenously and plasma leakage is observed using 
fluorescence microscopy. A challenge in utilizing IVM is to exteriorate and 
prepare the tissue without inducing an inflammatory response caused by the 
surgical procedure. Also, it is important to mimic physiological conditions 
regarding temperature and pH. Limitations of IVM of the hamster cheek 
pouch are that it is a time-consuming method that requires surgical skills for 
preparation of tissue, and that there is a risk of bias when selecting areas of 
tissue to be studied. To ensure representative data, five different 
microvascular sections were studied in each animal. In paper I, topical 
administration of LTB4 was used to induce neutrophil adhesion, and vascular 
permeability was assessed through monitoring leakage of FITC-dextran 
following different treatments.  
3.2.2 MODELS OF ACUTE INFLAMMATION IN MICE 
3.2.2.1 Pleurisy in mice 
This is a cavity model, meaning that an inflammatory stimulus is injected 
into either a created or an already existing body cavity. Other common cavity 
models are the peritonitis model and the subcutaneous air pouch model 
(Moore, 2003). The pleurisy model allows for parallel quantitative 
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assessment of immune cell recruitment as well as exudation of plasma. 
Pleurisy is induced by injection of an inflammatory stimulus into the pleural 
cavity of anaesthetized mice. In paper I, LTB4 and thioglycollate were used. 
Intravenous access was allowed by placing a catheter in the left jugular vein. 
This was performed to administer the plasma tracer FITC-dextran at the start 
of the experiment as well as to control depth of anesthesia during the four-
hour incubation. Following incubation, mice were euthanized and the pleural 
cavity was accessed by opening the thorax. The pleural exudate was collected 
and analyzed for volume (V), fluorescence intensity (FI) and neutrophil 
count. Neutrophil count was assessed by flow cytometry and plasma leakage 
was quantified by calculating the plasma clearance volume (permeability 
index, PI) based on the formula PI = FIexudate × Vexudate / FIserum. The use of PI 
for quantification takes into account both the volume of fluid that has leaked 
out into the pleural space as well as the degree of macromolecular leakage. 
Some limitations of this model are that mice are anesthetized throughout the 
experiment, that blood pressure is not monitored, and that there is a risk of 
causing a contaminating hemorrhage both during injection of inflammatory 
stimulus and during the surgical opening of the thorax. To minimize the risk 
of bleeding when accessing the pleural cavity the mice were bled by cutting 
the abdominal vena cava and aorta prior to collection of the exudate. 
3.2.2.2 Acute systemic inflammation in mice 
This method was used to investigate the acute inflammatory reaction in lung 
in response to a systemically administered stimulus. The model aims to 
mimic acute lung injury induced by systemic inflammation such as sepsis, 
and allows for assessment of immune cell accumulation and plasma leakage 
in lung. The protocol was based on previous work in our group (Soehnlein et 
al., 2008a), with some modifications. Female C57bl/6 mice were used in 
paper I and male Balb/c mice were used in paper II and III. Mice were 
anaesthetized with intraperitoneal injection of a mixture of ketamine and 
xylazine and were kept anaesthetized on a temperature-controlled heating 
plate throughout the experiment that lasted for 30 minutes. For intravenous 
access, a catheter was placed in the left jugular vein. Mice were stimulated 
with intravenous administration of heat-killed group A Streptococci (hkGAS) 
(paper I, II and III) or with synthetic polyphosphates (paper III). Evans blue 
dye, which binds albumin and becomes a marker for macromolecular 
leakage, was injected intravenously at the start of the experiment. After 30 
minutes, the jugular vein catheter was connected to a syringe pump, the 
abdomen was cut open and the abdominal aorta and vena cava were exposed. 
Both aorta and vena cava were clamped and an incision was quickly made in 
the aorta proximal to the clamp. Following this, the pump was started (600 
µl/min) and mice were perfused with 4 ml PBS supplemented with heparin. 
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Lungs where then collected and all lobes but the right medial lobe were dried 
over night for quantification of Evans blue in lung tissue. The right medial 
lobe was passed through a cell strainer and lung neutrophil accumulation 
was quantified by flow cytometry. Limitations with this model are similar to 
those in the pleurisy model as the mice as anesthetized and blood pressure is 
not monitored. Furthermore, it cannot discriminate between adhered and 
extravasated neutrophils since cell analysis is performed on homogenized 
lung tissue.  
3.2.2.3 Pulmonary inflammation in mice 
Several mouse models have been developed to study the inflammatory 
response during infectious and non-infectious pulmonary inflammation. 
Inflammatory stimuli can be administered by intratracheal instillation, 
whereby the stimulus is delivered through the trachea following surgical 
preparation in anaesthetized mice. Another, less invasive, method is 
administration of aerosolized stimuli in an aerosol inhalation chamber, 
which allows mice to be unrestrained and awake. Furthermore, inflammatory 
stimuli can be administered by intranasal inoculation whereby droplets 
placed on the nostrils are aspirated by the animal (Bielen et al., 2017). This 
method only requires brief anesthesia and a short duration of restraint. 
Following induction of pulmonary inflammation or infection, mice are then 
observed for a period of time and depending on the purpose and the read-out 
of the experiment mice are then sacrificed and samples are collected. When 
subjecting awake animals to pathogens or noxious stimuli, it is of high 
importance to have an established humane endpoint that may not be 
exceeded, and therefore animals should be observed for early detection of 
symptoms throughout the experiment. Sample collection can be done in 
many ways depending on the research question. A frequently used method is 
bronchoalveolar lavage (BAL) where a tube is inserted into the trachea and 
lungs are flushed with saline solution that is aspirated. This allows for 
collection of sample from the alveoli and is often used to analyze immune cell 
recruitment as well as protein content. Another option is to excise the lung 
tissue for immunohistochemistry or to homogenize the lung tissue for cell 
analysis or gene expression. A common way of quantifying edema formation 
is to excise and weigh the lung tissue in a “wet” state and then later on after 
drying, weighing it in a dry state, rendering a wet-dry weight. In paper IV, 
heat-killed Pseudomonas aeruginosa strain PAO1 (hkPAO1) was given by 
intranasal inoculation to mice briefly anaesthetized with Isoflurane. Mice 
were then observed and evaluated according to the score sheet for humane 
endpoint, and sacrificed at different time points. Following sacrifice, BAL 
was performed and BAL fluid was analyzed for immune cell content by flow 
cytometry as well as for protein content with ELISA. Lung tissue was then 
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harvested and homogenized, and subjected to quantitative polymerase chain 
reaction (qPCR). In separate experiments, mouse lungs were perfused in a 
similar manner as in the acute systemic inflammation model and then lung 
lobes were excised and weighed to quantify edema formation.  
3.2.2.4 Neutrophil and platelet depletion 
In paper I-III, neutrophil depletion was achieved by intraperitoneal injection 
of anti-Gr1 monoclonal antibody (Soehnlein et al., 2008b), and neutropenia 
was confirmed by peripheral blood cell count prior to experiment. In paper 
III, platelet depletion was accomplished by intraperitoneal injection of anti-
mouse thrombocyte serum (McDonald et al., 2012). 
 
3.3 IN VITRO METHODOLOGY 
3.3.1 FLOW CYTOMETRY  
Flow cytometry was utilized to quantify leukocytes in pleural exudate (paper 
I), in homogenized lung tissue (paper I-IV) and in BAL fluid (paper IV) in 
vivo, and to count transmigrated neutrophils in vitro (paper IV). For the in 
vivo experiments, cell suspensions were stained with anti-Gr-1 (Ly-6G/Ly-
6C) and anti-F4/80 antibodies and leukocytes were identified based on 
morphology with forward (cell size) and side (cell granularity) scatter, and 
then gated to exclude non-leukocytes. Neutrophils (Gr-1+, F4/80-), 
monocytes (Gr-1+, F4/80+) and macrophages (Gr-1-, F4/80+) were 
characterized based on different expression of Gr-1 and F4/80.  
3.3.2 ENDOTHELIAL AND EPITHELIAL CELLS 
Cultured endothelial cells (EC) are commonly used for research on 
inflammatory processes such as reorganization of the endothelial 
cytoskeleton and alterations in endothelial barrier function. Both 
immortalized endothelial cell lines and primary endothelial cells are 
frequently used, and may be more or less suitable depending on the research 
question. Studying the endothelial barrier in vitro has benefits in that it 
allows high-throughput testing of effects of various stimuli and treatments. 
Also, cell-type specific molecular mechanisms can by studied more easily 
than in vivo. However, there are some obvious limitations with studying an 
isolated cell type that normally is in contact with a basement membrane, 
extracellular matrix and other cell types such as pericytes. In vivo, EC are 
also continuously exposed to fluid shear stress that affects EC functions. 
Another factor is the heterogeneity of EC throughout the vasculature. 
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EC activation can be studied in real-time by loading EC with calcium 
indicators that emit fluorescence during increases in cytosolic calcium. 
Further, staining of the actin cytoskeleton in fixed cells can show actin stress 
fiber formation as a measure of EC activation. Barrier integrity of an EC 
monolayer and alterations in permeability can be assessed with 
measurement of transendothelial electrical resistance (TEER) that measures 
the resistance of an EC monolayer cultured on a semipermeable membrane. 
A transwell system, also known as a Boyden chamber, can be used to 
measure EC permeability through measuring the flux of dyes such as FITC-
dextran or Evans blue-conjugated albumin from an upper to a lower 
compartment separated by an EC monolayer. Such a transwell system can be 
used also to monitor transmigration of cells, such as neutrophils, across a 
naked membrane or a cell monolayer. 
In paper I and II, human umbilical vein endothelial cells (HUVEC) were used 
to study EC activation with cytoskeletal reorganization and intercellular gap 
formation following stimulation with isolated neutrophils together with 
hkGAS, or with supernatants from hkGAS-stimulated neutrophils. This was 
performed in the presence of purified HK. HUVEC are primary endothelial 
cells that were the first type of EC to be cultured in vitro (Nachman and Jaffe, 
2004). This method was chosen since it was stable and reproducible, and 
allowed a rather high throughput with several different treatments. A 
limitation of this method is that it entails an element of judgment when 
selecting areas for gap area quantification.  Also, the excessive gap formation 
might not directly reflect the situation in vivo since there is no basement 
membrane that can resist the contraction of EC. However, quantifying in 
vitro endothelial gap formation is still an eligible method for assessing EC 
activation and has been used in previous studies (Duah et al., 2013). 
In paper I, HUVEC were utilized when studying the proteolysis of EC-bound 
HK, and also the human endothelial hybrid cell line (EA.hy926) for studying 
the displacement of HK from ECs. EA.hy926 is a hybrid cell line of HUVEC 
and carcinoma cells with preserved EC properties such as contact inhibition 
and expression of common endothelial markers (Bouis et al., 2001). In this 
experiment, the endothelial cells were considered as a scaffold with GAGs for 
HK to interact with. 
In paper IV, the human lung epithelial cell line BEAS-2B was stimulated with 
phenylbutyrate (PBA) and heat-killed Pseudomonas aeruginosa (hkPAO1), 
and supernatant was used in a chemotaxis assay with neutrophils. 
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3.3.3 NEUTROPHILS AND PLATELETS 
3.3.3.1 Neutrophil experiments 
Neutrophils, or PMNs, were obtained from venous blood collected in EDTA-
coated tubes. The protocol for isolation was based on work previously 
described (Nauseef, 2007). Isolation is a three-step process where whole 
blood is first mixed with dextran that initiates red blood cell (RBC) 
sedimentation. An upper layer of leukocyte-rich plasma can then be aspirated 
and layered on top of Ficoll-Paque. Ficoll-Paque is a density gradient 
medium and following centrifugation neutrophils and some remaining RBC 
are located in the pellet. The supernatant that contains lymphocytes, 
monocytes, basophils and platelets, is discarded. The final step is to get rid of 
the remaining RBC by hypotonic cell lysis with H2O.    
For preparation of neutrophil secretion (paper I and II), isolated human 
neutrophils were stimulated with hkGAS under gentle rotation for 30 
minutes, centrifuged, and the supernatant was stored at -20°C until use.   
A neutrophil adhesion assay was employed in paper II. Neutrophils were 
allowed to adhere to bovine serum albumin (BSA)-coated plates, with or 
without hkGAS and sevuparin. After washing of plate wells, remaining 
adherent neutrophils were lysed and MPO activity was measured to quantify 
neutrophil adhesion.  
Neutrophil degranulation following stimulation with hkGAS, synthetic polyP 
or platelet supernatant was studied in paper II and III. Subsequent to 
stimulation, with or without different treatments, neutrophil suspensions 
were centrifuged and MPO activity in supernatant was analyzed as a measure 
of degranulation.  
In paper IV, the chemotactic activity of PBA was investigated in a transwell 
system with an upper and a lower chamber separated by a membrane (pore 
size 3 µm). In brief, PBA together with hkPAO1, or supernatant from lung 
epithelial cells stimulated with PBA and hkPAO1, was added to the lower 
chamber. Isolated neutrophils were then added to the upper chamber and 
after two hours incubation, migrated neutrophils were quantified by flow 
cytometry.  
3.3.3.2 Neutrophil stimulation with platelet secretion 
In paper III, blood from healthy volunteers was collected in sodium citrate 
tubes and prostaglandin E1 was directly added to avoid platelet activation. 
Platelet-rich plasma was collected following centrifugation and platelets were 
pelleted and resuspended. Platelet concentration was determined with 
manual cell count following stain with Stromatol. Platelet secretion was 
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prepared by stimulating platelets with adenosine diphosphate (ADP) and 
supernatant was collected after centrifugation. Neutrophils and platelet 
secretion at a ratio of 1:100 from the same donor were then incubated with or 
without treatment with polyP inhibitor and MPO activity was analyzed as a 
measure of neutrophil degranulation.  
3.3.4 BACTERIA  
In paper I-III, heat-killed group A Streptococcus (GAS, Streptococcus 
pyogenes) (clinical isolate, emm 87), and in paper IV, heat-killed 
Pseudomonas aeruginosa (PAO1) were used for in vivo and in vitro 
experiments. Bacteria were cultured in Brain Heart Infusion broth at 37°C, 
washed and resuspended in PBS. Heat-killing was performed by incubation 
at 100°C for 1 hour (PAO1) or a minimum of 3 hours (GAS). 
3.3.5 PROTEIN ASSAYS 
3.3.5.1 Western blot of HK 
Western blot is a common method for detecting specific proteins in 
homogenized tissue samples. In paper I, western blot was used to assess 
proteolysis of EC-bound HK. HUVEC were incubated with human citrated 
plasma together with neutrophils or granule proteins. EC were washed and 
lysed followed by separation by gel electrophoresis. Proteins were transferred 
to a nitrocellulose membrane and HK was detected by enhanced 
chemiluminescence with sheep anti-human HK antiserum (AS88) that 
detects heavy and light chains of HK. Signal intensity of HK was measured by 
densitometry with Quantity One software. To control for even loading, 
protein concentration in cell lysate or a second stain of the membrane for the 
housekeeping protein β-actin was performed.  
3.3.5.2 HK competition assay 
In paper I, we used an assay for quantifying competitive binding of proteins 
to immobilized heparan sulfate and cultured EC. The protein of interest, HK, 
was radiolabeled with Iodine-125 (125I-HK) and incubated together with 
different concentrations of FXIIa, neutrophil elastase or HBP onto either 
heparan sulfate or EC. Following incubation, plates were washed and the 
amount of bound HK to either scaffold was quantified using a gamma 
counter.  
3.3.5.3 Enzyme activity assays 
In paper I, the enzymatic activity of PK was analyzed using the chromogenic 
substrate S-2302 following incubation with supernatant from hkGAS-
stimulated neutrophils. Cleavage of chromogenic substrates results in 
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formation of color that can be analyzed with a spectrophotometer. The rate 
by which color appears is proportional to the enzymatic activity, making this 
a simple and useful tool for assessment of activity of various enzymes in 
different settings and following treatment with different inhibitors. 
In paper II, enzymatic activity of neutrophil elastase was analyzed in 
supernatant from hkGAS-stimulated neutrophils following incubation with 
different doses of sevuparin. The fluorogenic substrate MeOSuc-AAPV-AMC 
was used for quantification of enzymatic activity, which corresponds to the 
rate of increase in fluorescence intensity measured in a fluorometer.  
In paper II and III, the activity of MPO was measured. In the neutrophil 
adhesion assay in paper II, MPO was measured in cell lysate as a means to 
quantify the number of adhered neutrophils. In paper II and III, neutrophil 
degranulation was quantified by measuring MPO activity in neutrophil 
supernatant. This assay was previously described (Suzuki et al., 1983) and in 
brief, it utilizes the capacity of MPO to form hypochlorous acid (HOCl) out of 
hydrogen peroxide (H2O2), that in turn oxidizes the substrate TMB (3,3’,5,5’-
tetramethylbenzidine). TMB then develops into a blue reaction product that 
can be measured with a spectrophotometer. By using an MPO standard 
dilution series in parallel, the MPO activity can be determined.  
3.3.5.4 Enzyme-linked immunosorbent assay (ELISA) 
In paper IV, ELISA was employed to measure concentrations of murine TNF, 
IL-6 and IL-10 in BAL fluid. ELISA is a plate-based assay frequently used for 
determining quantitative measures of antigens and antibodies, and can be 
performed in many different ways depending on the analyte in question. For 
these experiments we used ready-made ELISA kits from Thermo Fisher 
Scientific.  
3.3.6 AFFINITY CHROMATOGRAPHY (AC) 
In paper II, two different AC techniques were utilized to assess which 
neutrophil-derived proteins are bound by sevuparin and heparin. AC can be 
designed in many different ways to suit the task at hand, but essentially it is a 
method for separation of molecules from a complex solution. Supernatant 
from hkGAS-stimulated neutrophils was passed through a commercial 
column of heparin-coated sepharose and flow-through was collected. Also, 
neutrophil secretion was mixed with a sevuparin-coated sepharose matrix, 
and after incubation and centrifugation the supernatant was collected. This 
AC technique is called a batch procedure. 
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3.3.7 MASS SPECTROMETRY 
In paper II, liquid chromatography-mass spectrometry (LC-MS) was used to 
perform proteomic analysis of supernatant from hkGAS-stimulated 
neutrophils (carried out by Proteomics Karolinska). Protein content in 
untreated supernatant was compared with supernatant subjected to either 
sevuparin or heparin AC in terms of fold change of individual protein 
abundance. LC-MS is a common method used to identify components of a 
complex biological sample such as serum, urine or supernatants from cell 
suspensions. In brief, the mixture is subjected to protein digestion and the 
resulting peptides are separated with LC. The peptides are then eluted and 
transferred to a mass spectrometer that ionize and analyze the peptide’s 
mass-to-charge ratio. The proteins can then be identified by checking the MS 
spectra against a database for MS spectra and human proteins such as the 
UniProt human database. Relative quantity of the identified proteins can also 
be retrieved.  
3.3.8 POLYMERASE CHAIN REACTION (PCR) 
In paper IV, reverse transcription (RT)-PCR and quantitative (q) PCR were 
performed to analyze the gene expression levels of Cramp, Tnf, Cxcl1, Alox5, 
Alox15 and Ptgs2 (COX-2) in homogenized lung tissue at several time-points 
following administration of hkPAO1 and PBA. In brief, RNA was isolated 
from tissue by passing tissue lysate through a commercial column (RNeasy 
kit, Qiagen), followed by cDNA synthesis using RT-PCR. Next, cDNA was 
subjected to qPCR and alterations in gene expression were assessed and 
normalized for the housekeeping genes Hprt, Hmbs and Gapdh.  
 
3.4 STATISTICS 
Results are presented as means ± standard error of the mean (SEM). 
Statistical differences were analyzed with GraphPad Prism 5 using 1-way 
ANOVA with Tukey’s multiple comparisons test, repeated measures ANOVA 
followed by Bonferroni’s or Tukey’s post-hoc tests, one-tailed Mann-Whitney 
U test or two-tailed unpaired t-test. Differences were considered significant if 
P < 0.05. 
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 RESULTS & DISCUSSION 4.
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This thesis work focused on the role of neutrophils in regulation of 
endothelial barrier function in acute inflammation. Mechanisms contributing 
to neutrophil-mediated alterations of vascular permeability have been 
studied extensively by our research group and others, and although several 
mechanisms are already established the map is far from complete. In the 
following section, a synopsis of the results that constitute this thesis will be 
discussed. More detailed information is available in the individual papers.  
 
4.1 NEUTROPHIL-INDUCED EC BARRIER DISRUPTION AND 
PLASMA LEAKAGE 
Neutrophils induce plasma leakage (Wedmore and Williams, 1981) following 
adhesion via β2 integrins (Arfors et al., 1987). In paper I, neutrophil-
dependent increase in vascular permeability was assessed in the 
microcirculation of the hamster cheek pouch and in the mouse pleurisy 
model with the neutrophil chemoattractant LTB4. Topical application of LTB4 
onto the hamster cheek pouch induced leukocyte adhesion to the vessel walls 
of postcapillary venules and concurrent plasma leakage as imaged by light 
and fluorescence microscopy respectively (Figure 1A). In the mouse 
pleurisy model, which allows for quantification of neutrophil extravasation 
and plasma leakage, LTB4 injected into the pleural cavity induced neutrophil 
recruitment and plasma leakage. Plasma leakage, as measured by the volume 
of exudate as well as the amount of the fluorescent plasma tracer FITC-
dextran, was averted in mice subjected to neutrophil depletion and following 
blockage of the β2 integrin-subunits CD11a and CD11b (Figure 1B-C).  
In paper I, II and III, neutrophil-dependent plasma leakage was also 
demonstrated in a mouse model of acute systemic inflammation with hkGAS. 
M protein, a virulence factor of GAS, has previously been shown to activate 
neutrophils via β2 integrins (Herwald et al., 2004). Intravenous 
administration of hkGAS induced accumulation of neutrophils and an 
increase in plasma exudation in lung tissue, and in neutropenic mice, plasma 
leakage was abolished (Figure 2C-D).  
To study the effects of neutrophils on the endothelial barrier function in a 
human setting, cultured primary endothelial cells from human umbilical vein 
(HUVEC) were stimulated with human neutrophils together with hkGAS 
(paper I and II). Incubation of endothelial cells with either quiescent 
neutrophils or hkGAS alone caused no alterations of the integrity of the 
endothelial barrier. However, simultaneous stimulation with neutrophils and 
hkGAS induced EC remodeling and formation of interendothelial gaps. 
Binding of β2 integrins, either by adhesion to EC or with streptococcal  
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Figure 1. Neutrophil-induced endothelial gap formation and vascular leakage. 
A) Vascular leakage in postcapillary venules of hamster cheek pouch following stimulation 
with LTB4 and bradykinin. B1R-ant=B1 receptor antagonist, B2R-ant=B2 receptor antagonist, 
PK-inh=plasma kallikrein inhibitor B) Plasma leakage (permeability index) and C) 
neutrophil recruitment in LTB4-induced pleurisy in mice. PMN-depl = neutrophil depletion. 
D) HUVEC monolayers stained for F-actin after stimulation with human neutrophils (PMN) 
and hkGAS. E) Gap formation quantification in HUVEC monolayers following stimulation 
with secretion from hkGAS-activated human neutrophils. 
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M protein, results in neutrophil degranulation, which is known to induce 
vascular leakage and lung damage (Gautam et al., 2000, Herwald et al., 
2004, Soehnlein et al., 2008a). Indeed, blocking β2 integrins on neutrophils 
with an anti-CD18 antibody prior to stimulation with hkGAS completely 
prevented EC barrier disruption (Figure 1D).  
Neutrophil-derived proteins such as HBP are released from activated 
neutrophils and cause derangement of the EC barrier (Gautam et al., 2001, 
Herwald et al., 2004, Di Gennaro et al., 2009). In line with this, we 
stimulated HUVEC with supernatant from neutrophils incubated with 
hkGAS and found that supernatant from either unstimulated neutrophils or 
from hkGAS alone did not affect the EC layer, but supernatant from hkGAS-
stimulated neutrophils induced EC barrier disruption (paper I and II). 
Pretreatment of neutrophils with an anti-CD18 antibody prior to stimulation 
with hkGAS rendered the supernatant inactive on EC, confirming the role of 
β2 integrins for neutrophil degranulation with streptococcal M protein 
(Figure 1E).  
To investigate whether the effect of neutrophil secretion on EC was simply 
cytotoxic or involved previously established cell-signaling pathways, EC were 
pre-treated with the calcium chelator BAPTA-AM and the Rho kinase 
inhibitor fasudil prior to stimulation with neutrophil secretion. Both BAPTA-
AM and fasudil partly inhibited EC gap formation and the combination of 
both had an additive effect, resulting in near complete inhibition (Figure 
1E). These results suggest that neutrophil secretory products cause EC 
remodeling and gap formation via Rho kinase and increased actomyosin 
interaction, and are in line with previous findings (Breslin and Yuan, 2004).   
 
4.2 NEUTROPHIL-EVOKED PLASMA LEAKAGE IS 
MEDIATED BY THE KALLIKREIN-KININ SYSTEM 
Neutrophil-derived proteins released upon activation disrupt the endothelial 
barrier and cause vascular leakage. Furthermore, bradykinin (BK) and 
similar kinins, the end-products of the KKS, are known to increase vascular 
permeability, and neutrophil-derived proteases such as neutrophil elastase 
and proteinase 3 have previously been shown to liberate vasoactive kinins 
from kininogen (Imamura et al., 2002, Stuardo et al., 2004, Kahn et al., 
2009). In paper I, we therefore investigated a potential role of the KKS in 
neutrophil-mediated vascular hyperpermeability.  
In the previously stated in vivo models of acute inflammation with 
neutrophil-dependent plasma leakage, we found that inhibition of the KKS 
attenuated plasma leakage. In the hamster cheek pouch, antagonizing BK 
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receptors and inhibition of PK resulted in decreased plasma leakage (Figure 
1A), and the inhibitors had similar effects in the pleurisy model and in the 
model of acute systemic inflammation with hkGAS (Figure 2C-D). 
Furthermore, mice lacking either the BK B2 receptor or FXII presented with 
attenuated plasma leakage as compared to wild-type mice in the pleurisy 
model (Figure 2A-B).     
 
 
Figure 2. Neutrophil-induced vascular leakage involves the KKS. A) Plasma 
leakage (permeability index) and B) neutrophil recruitment in LTB4-induced pleurisy in 
mice. BdkB2-/- = BK B2 receptor knockout mice, F12-/- = factor XII knockout mice. C) Lung 
plasma leakage and D) lung neutrophil accumulation in hkGAS-induced acute systemic 
inflammation in mice. B2R-ant = B2 receptor antagonist, PMN-depl = neutrophil depletion. 
E) Western blot signal intensity of EC-bound HK normalized to mean control for each 
experiment. HBP = heparin-binding protein, P3, = proteinase 3, CG = cathepsin G, NE = 
neutrophil elastase. D) HUVEC monolayer gap formation quantification.  
 
 
To further investigate the mechanisms by how the KKS mediates neutrophil-
evoked plasma leakage, HUVEC (pre-incubated with purified HK) were 
treated with the B2 receptor antagonist and stimulated with human 
neutrophils and hkGAS, and also with supernatant from hkGAS-activated 
neutrophils. In both cases, blockage of the B2 receptor inhibited EC 
remodeling and gap formation (Figure 1E). Bradykinin B2-receptor-
mediated endothelial cell signaling has previously been suggested to involve 
both actomyosin contraction (Ma et al., 2012), which is confirmed by our 
data, and VE-cadherin disassembly (Orsenigo et al., 2012). Our results do not 
rule out VE-cadherin disassembly and possibly both mechanisms contribute.  
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Next, proteolysis of HK on HUVEC, with implicit kinin formation, was 
assessed following neutrophil activation. HUVEC were pre-incubated with 
human plasma (as a source of HK) and stimulated with hkGAS or LTB4 with 
or without neutrophils. Alternatively, HUVEC were incubated with TNF prior 
to addition of neutrophils. TNF activates EC and thereby stimulates 
neutrophil adhesion and degranulation. A significant degradation of HK, as 
measured by Western blot, was found with all three stimuli of neutrophil 
activation implicating neutrophil-induced kinin formation. Furthermore, 
incubation of PK and FXII, proteases known to mediate HK cleavage, with 
supernatant from hkGAS-activated neutrophils induced plasma kallikrein 
activation. Previous studies have shown that neutrophil granule proteins can 
induce kinin formation by direct proteolysis of HK (Imamura et al., 2002, 
Stuardo et al., 2004, Kahn et al., 2009), and our results suggest an additional 
indirect pathway for HK cleavage whereby neutrophil-derived proteins 
trigger activation of the PK/FXII loop. 
With the aim to further characterize the mechanisms by which neutrophil-
derived proteins act on HK, we utilized an assay for competitive binding of 
HK to GAGs. HK is known to bind GAGs on EC (Renne et al., 2000), and as a 
regulatory mechanism for BK formation a previous study found that HK is 
protected from proteolysis whilst bound, but is made available upon 
displacement from GAGs (Renne et al., 2005). HBP and the other 
serprocidins (NE, P3 and CG) have all previously been shown to increase EC 
permeability (Gautam et al., 2001, Bentzer et al., 2016, Peterson et al., 1987, 
Peterson, 1989). In contrast to the other serprocidins, HBP lacks proteolytic 
activity (Campanelli et al., 1990), but its structure favors binding to 
negatively charged GAGs (Olofsson et al., 1999). We hypothesized that HBP 
binds to GAGs following neutrophil degranulation and displaces HK that is 
then made available for proteolytic cleavage. Indeed, HBP was found to dose-
dependently outrival HK from binding to heparan sulfate and EC, in contrast 
to the proteases NE and activated FXII. Furthermore, supporting our 
hypothesis, HBP potentiated the effects of NE, P3 and CG in causing 
proteolysis of EC-bound HK (Figure 2E) and in mediating BK B2 receptor-
mediated EC gap formation in HUVEC monolayers (Figure 2F). Together 
these results suggest that during neutrophil adhesion and subsequent 
degranulation, HBP paves the way for BK formation by displacing HK and 
making it accessible to proteases such as PK, NE, P3 and CG. This event 
possibly only occurs in the sheltered compartment created between the EC 
and the adherent leukocyte, where an optimal milieu with lesser amounts of 
plasma protease inhibitors is created (Loike et al., 1992) (Figure 3). In 
support of this, EC gap formation induced by hkGAS-stimulated neutrophils 
was prevented in the presence of human plasma, as compared to incubation 
with buffered saline and purified HK (unpublished results).  
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Figure 3. Proposed mechanism for neutrophil-induced vascular leakage. 
Neutrophil activation via β2 integrins results in release of granule proteins into a shielded 
compartment between neutrophil and EC. Here, HBP displaces the HK/PK complex from 
GAGs which enables proteolytic processing of HK/PK by neutrophil and plasma proteases. 
Proteolysis of HK liberates BK that induces EC actin stress fibers and gap formation via BK 
receptors.  
 
A previous study suggested that TNF is released from activated neutrophils 
and is responsible for causing neutrophil-induced plasma leakage 
(Finsterbusch et al., 2014). We investigated these findings in our model 
systems and found no such effects either in vitro with stimulation of TNF on 
EC, as well as treatment with a TNF-inhibitor on PMN-secretion-stimulated 
EC, or in vivo using a TNF-inhibitor in mice subjected to intravenous hkGAS.  
Vascular leakage is a central feature in severe microbial infections such as 
sepsis, and neutrophil degranulation and HBP release following stimulation 
with GAS-derived M protein has previously been shown to cause lung injury 
(Herwald et al., 2004, Soehnlein et al., 2008a). Furthermore, the KKS 
together with HBP has previously been found to take part in the pathogenesis 
of erysipelas caused by GAS (Linder et al., 2010). However, neutrophil 
activation and release of HBP is not confined to infections with GAS, as 
several studies have suggested HBP as a promising biomarker of hypotension 
and organ dysfunction in sepsis with different pathogens (Fisher and Linder, 
2017). Neutrophils and the KKS are also suggested as mediators of vascular 
leakage in the pathogenesis of infection with hantavirus (Koma et al., 2014, 
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Taylor et al., 2013). Supporting this, two case reports of patients with 
hantavirus infection with capillary leakage syndrome and respiratory failure 
describe significant clinical recovery after treatment with the BK B2 receptor 
antagonist HOE 140/icatibant (Antonen et al., 2013, Laine et al., 2015). 
Collectively, there is evidence by us and others that indicates the KKS as a 
potential target in treatment of neutrophilic inflammatory disease conditions 
with vascular leakage. However, in contrast to this, a study of porcine Gram-
negative sepsis with N. meningitis found no improvement in capillary 
leakage after treatment with icatibant (Barratt-Due et al., 2011). Possibly, the 
KKS is predominantly involved in mediating vascular leakage during 
infections with pathogens that strongly stimulate neutrophil activation and 
degranulation. Neutrophils do respond differently depending on the 
pathogen, and GAS has been found to induce neutrophil degranulation and 
HBP release more efficiently than S. aureus or E. coli (Snall et al., 2016). 
In all, paper I shows a role for the KKS in mediating neutrophil-evoked 
plasma leakage in acute inflammation and propose a mechanistic basis for 
how neutrophil-derived proteins act in concert to induce BK formation and 
EC barrier disruption. Further, it presents a possible target for preventing 
excessive vascular leak in neutrophilic inflammation.  
 
4.3 SEVUPARIN INHIBITS STREPTOCOCCUS-INDUCED 
VASCULAR LEAKAGE BY NEUTRALIZING NEUTROPHIL-
DERIVED PROTEINS 
In paper II, the role of neutrophil-derived proteins in the acute inflammatory 
response was further investigated. We hypothesized that the heparin 
derivative sevuparin could inhibit the activity of neutrophil-derived proteins 
and thus prevent neutrophil-induced vascular leakage caused by hkGAS. 
Sevuparin is a low-anticoagulant heparinoid developed for preventing vaso-
occlusion in malaria and sickle cell disease (Vogt et al., 2006, Telen et al., 
2016). It is a derivative of heparin where the high-affinity antithrombin III-
binding pentasaccharide has been removed, rendering it inactive on factor Xa 
and thrombin. 
The effect of sevuparin was investigated in the mouse model of acute 
systemic inflammation with hkGAS. Sevuparin attenuated lung plasma 
leakage to the same extent as neutrophil depletion, whilst not affecting 
neutrophil accumulation (Figure 4A-B). In line with this, sevuparin 
significantly inhibited in vitro EC gap formation caused by hkGAS-
stimulated neutrophils.  
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To further elucidate by which mechanism sevuparin altered neutrophil-
evoked effects on the endothelial barrier, in vitro neutrophil adhesion and 
degranulation assays were employed. Sevuparin did not inhibit either 
adhesion or degranulation of neutrophils, in contrast to previous studies 
showing inhibition of these activities with other heparin derivatives (Peter et 
al., 1999, Brown et al., 2003). However, sevuparin treatment of secretion 
from hkGAS-stimulated neutrophils significantly decreased the enzymatic 
activity of NE and attenuated EC gap formation, suggesting that sevuparin 
targets components released from activated neutrophils (see paper II).  
 
 
Figure 4. Sevuparin attenuates lung plasma leak, and affinity chromatography 
(AC) with sevuparin-coated beads renders neutrophil secretion inactive. A) 
Lung plasma leakage and B) lung neutrophil accumulation in hkGAS-induced acute systemic 
inflammation in mice. PMN-depl = neutrophil depletion. C) HUVEC monolayer gap 
formation following stimulation with secretion from hkGAS-activated human neutrophils, 
with or without AC with sevuparin-coated beads. D) Flowchart for identifying neutrophil-
derived proteins with EC barrier-disrupting effects using AC and mass spectrometry. 
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Next, secretion from hkGAS-activated neutrophils was subjected to affinity 
chromatography (AC) with sevuparin-conjugated sepharose beads or with a 
heparin column. Post-AC supernatants from both sevuparin- and heparin-AC 
completely lacked disruptive effects on EC, indicating that the neutrophil 
secretion components responsible for effects on EC were eliminated by 
binding the polysaccharides (Figure 4C). Mass spectrometry analysis of 
neutrophil secretion and post-AC supernatants was then performed to find 
out which neutrophil-derived proteins that interacted with sevuparin and 
heparin, implicitly the proteins responsible for EC barrier disruption. Over 
400 proteins were identified in the secretion from hkGAS-activated 
neutrophils and the relative quantity of the individual proteins was compared 
before and after AC with sevuparin and heparin. Comparison rendered a list 
in order of how much the proteins had decreased in quantity following AC. 
An assumption was made that the proteins responsible for the disruptive 
effects on EC were proteins that were most efficiently removed by AC 
(inclusion criterion of >2-fold change in relative quantity). Also, since post-
AC supernatants from either sevuparin or heparin AC had no effects on EC, it 
was concluded that proteins found in only one of the clusters could not be 
responsible for the disruptive effects on EC. After including proteins that had 
decreased in quantity more than 2-fold after either sevuparin or heparin AC, 
and after excluding proteins only found in one of the lists, 18 proteins 
remained (Figure 4D and Table 2).  
Several of the proteins in table 2 have previously established disruptive 
effects on EC. The granule-derived serprocidins (HBP, NE, P3, CG) were all 
found to effectively bind sevuparin. Furthermore, the granule protein MPO, 
as well as EPO and ECP, also bound sevuparin to a high degree. Besides 
proteins of granular origin with documented permeability-increasing effects 
on EC, the nucleus-derived histone H4 and the cytoplasmic proteins S100A8, 
S100A9 and S100A12 all strongly interacted with sevuparin. Protein S100A8 
and S100A9 together form the heterodimer complex calprotectin with known 
antimicrobial effects and that is used as a biomarker for inflammatory bowel 
disease (Burri and Beglinger, 2014). In a study by Urban and colleagues, 
proteomic analysis of the constituents of neutrophil extracellular traps 
(NETs) identified proteins of granular, nuclear as well as cytosolic origin 
(Urban et al., 2009). Of the NET-associated proteins they found, several were 
the same as the proteins that we identified. Although we did not investigate 
the presence of NETs in paper II, these results imply that hkGAS stimulated 
NETosis. In support of this, GAS has previously been found to induce release 
of NETs (Lauth et al., 2009). Deoxyribonuclease I (DNAse I) is known to 
break down NETs by cleaving DNA strands and is frequently used in 
experimental studies investigating the role of NETs. In the mouse model of 
acute systemic inflammation with hkGAS, DNAse I treatment only had a 
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minor inhibitory effect on lung plasma leakage and no effect on lung 
neutrophil accumulation, whereas cell-free DNA in serum was substantially 
decreased as compared to untreated mice (unpublished results).  
 
Table 2. Neutrophil-derived proteins bound by both sevuparin and heparin. 
Protein name UniProt 
Fold change post ACA 
(% remaining) Known disruptive or 
protective effect on EC 
barrier Sevuparin Heparin 
EPO P11678 Infinite (0.0%) 3.0 (33.2%) Disruptive (Minnicozzi et al., 1994) 
Bactericidal permeability-
increasing proteinB P17213 Infinite (0.0%) 2.4 (41.5%) 
Protective 
(Arditi et al., 1994) 
Cathepsin G P08311 269.3 (0.4%) 4.5 (22.4%) Disruptive (Kenne et al., 2019) 
Azurocidin, HBP P20160 38.5 (2.6%) 18.9 (5.3%) Disruptive (Gautam et al., 2001) 
Protein S100-A12 P80511 22.4 (4.5%) 11.5 (8.7%) Disruptive (Wittkowski et al., 2007) 
Lactotransferrin P02788 14.5 (6.9%) 51.6 (1.9%) Protective (Erga et al., 2001) 
Annexin A3 P12429 9.2 (10.9%) 2.2 (45.7%) No known 
Histone H4 P62805 9.0 (11.1%) Infinite (0%) Disruptive (Xu et al., 2009) 
MPO P05164 5.85 (17.1%) 23.3 (4.3%) Disruptive (Patterson et al., 2014) 
Neutrophil elastase P08246 5.7 (17.7%) 21.7 (4.6%) Disruptive (Peterson et al., 1987) 
ECP, RNAse 3 P12724 5.3 (18.8%) 9.4 (10.7%) Disruptive (Minnicozzi et al., 1994) 
Cathelicidin antimicrobial 
peptide, LL-37 P49913 5.0 (20.2%) 5.9 (17.1%) 
Protective 
(Byfield et al., 2011) 
Metalloproteinase 
inhibitor 2, TIMP-2 P16035 4.3 (23.1%) Infinite (0%) 
Protective 
(Kim et al., 2012) 
Myeloblastin, Leukocyte 
proteinase 3 P24158 2.9 (34.2%) 4.8 (20.7%) 
Disruptive 
(Kenne et al., 2019) 
Protein S100-A8 P05109 2.6 (38.2%) 33.1 (3.0%) Disruptive (Wang et al., 2014) 
Protein S100-A9 P06702 2.4 (42.2%) 36.8 (2.7%) Disruptive (Wang et al., 2014) 
Olfactomedin-4 Q6UX06 2.2 (45.6%) 2.8 (35.8%) No known 
Platelet basic protein P02775 2.0 (49.8%) 2.1 (47.3%) No known 
AValues from 2 separate analyses comparing neutrophil secretion after sevuparin and heparin AC with 
untreated neutrophil secretion. 
 
 
 
The effects of heparin on the inflammatory and coagulative processes 
involved in sepsis are under investigation, and as of today, heparin’s role as a 
therapeutic in sepsis remains conflicting (Li and Ma, 2017). Modified low-
anticoagulant derivatives of heparin might prove beneficial due to a reduced 
risk of adverse bleeding. Similar to the effects we find with sevuparin, other 
variants of low-anticoagulant heparin have also been found to bind 
neutrophil-derived proteins such as HBP, S100 proteins and histones, as well 
as to prevent lung damage and improve survival in sepsis (Rao et al., 2010, 
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Wildhagen et al., 2014). Sevuparin is negatively charged and electrostatic 
charge interaction is therefore likely the mechanism for neutralizing the 
cationic neutrophil-derived proteins.    
Taken together, paper II confirms the significant role of neutrophil secretory 
products in causing vascular leakage in acute inflammation and presents 
sevuparin as a potential therapeutic.   
 
4.4 POLYPHOSPHATES ACTIVATE NEUTROPHILS AND 
CAUSE LUNG PLASMA LEAKAGE 
Besides neutrophils, platelets are also highly involved in the acute 
inflammatory response by forming platelet-neutrophil complexes and 
contributing to neutrophil activation through several proposed mechanisms. 
Inorganic polyphosphates (polyP) are released from granules upon platelet 
activation, and has been shown to increase EC barrier permeability by direct 
effects on EC, but also via activation of the KKS. Furthermore, a recent study 
suggested platelet polyP as a novel regulator of neutrophil activation by 
inducing NET formation in thromboinflammation (Chrysanthopoulou et al., 
2017).  
 
 
Figure 5. Platelet polyphosphates (polyP) induce neutrophil degranulation. A) 
Myeloperoxidase (MPO) activity in in supernatant of human neutrophils stimulated with 
polyP of different polymer lengths. PolyP 90 = 90 phosphate units, PolyP 630 = 630 
phosphate units, PolyP inhibitor = PAMAM dendrimer generation 1.0. B) MPO activity in 
supernatant of neutrophils stimulated with either adenosine diphosphate (ADP) or 
supernatant (Pl super) from unstimulated or ADP-stimulated platelets, with or without polyP 
inhibitor.  
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In paper III the aim was to investigate platelet polyP as an activator of 
neutrophils and its potential role in neutrophilic systemic inflammation. 
Isolated neutrophils were incubated with synthetic polyP of various polymer 
lengths and MPO release was analyzed as a measure of neutrophil 
degranulation. PolyP released from platelets was previously shown to be 60-
100 phosphate residues long (Ruiz et al., 2004, Muller et al., 2009) and 
longer polymers of platelet polyP have been suggested to be presented on the 
surface of activated platelets as insoluble nanoparticles (Verhoef et al., 2017). 
PolyP with polymer lengths of 90 and 630 phosphate units induced 
neutrophil degranulation that was attenuated in the presence of a polyP 
inhibitor (PAMAM dendrimer generation 1.0) (Figure 5A) previously found 
to target polyP by charge interaction (Smith et al., 2012). Furthermore, 
neutrophils were incubated with supernatant from activated platelets with or 
without polyP inhibitor, with similar results. (Figure 5B).  
Next, the potency of polyP in mediating neutrophil-induced lung edema was 
assessed in mice. Intravenous administration of synthetic polyP 630 induced 
lung plasma leakage that was prevented in both neutropenic mice and in 
mice treated with the polyP inhibitor (Figure 6A-B). Furthermore, polyP 
630 increased lung neutrophil accumulation that was not diminished with 
the polyP inhibitor. In contrast, polyP 90 did not induce any increases in 
neutrophil accumulation or lung plasma leakage. Previous studies, 
investigating the impact of polyP polymer length on its proinflammatory and 
procoagulant capacity, have shown that longer polymers (i.e. >500 units) 
increase EC permeability at lower concentrations than shorter polymers (i.e 
60-100 units), and that longer polymers induce FXII activation to a higher 
degree than shorter polymers (Dinarvand et al., 2014, Smith et al., 2010, 
Wang et al., 2019). With regards to the discrepancy of our results with polyP 
90 and 630 in vivo, since in vitro neutrophil degranulation did not differ, a 
possible explanation might be that polyP 90 is more easily degraded by 
endogenous phosphatases.  
Targeting polyP has previously been suggested as a therapeutic strategy in 
inflammatory disease (Smith et al., 2012). After having shown that polyP 
induced neutrophil degranulation and neutrophil-mediated vascular leakage, 
we therefore investigated the role of platelet polyP in the more clinically 
relevant mouse model of acute systemic inflammation with hkGAS. Platelet-
depletion decreased lung neutrophil accumulation as compared to platelet-
competent mice, whereas effect on plasma leakage was difficult to interpret 
due to focal hemorrhages in lung tissue (Figure 6C-D). Treatment of mice 
with the polyP inhibitor decreased lung plasma leakage, but also increased 
lung neutrophil accumulation (Figure 6C-D).  That lung plasma leakage 
was decreased supports a role for polyP in the systemic inflammatory 
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response caused by hkGAS. Furthermore, that lung neutrophil accumulation 
was increased with the polyP inhibitor might indicate cytotoxicity, which is a 
known adverse effect of PAMAM dendrimers (Sadekar and Ghandehari, 
2012, Durocher and Girard, 2016).  
 
 
 
 
Figure 6. PolyP inhibition decreases lung plasma leakage in acute systemic 
inflammation in mice. A and C) Lung plasma leakage and B and D) neutrophil 
accumulation in mice subjected to intravenous injection of polyP 90, polyP 630 or hkGAS. 
PMN-depl = neutrophil depletion, PolyP inh = PAMAM dendrimer, Platelet-depl = platelet 
depletion. 
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Paper I showed that neutrophil-mediated vascular leakage involves 
activation of KKS and BK formation. FXII, the initiator of KKS activation 
together with PK, also initiates the intrinsic pathway of coagulation. In a 
previous study, platelet polyP was suggested as the missing link between 
primary and secondary hemostasis by activating FXII, and also as a novel 
mediator of inflammation by inducing BK formation (Muller et al., 2009). 
These findings were however questioned by others that concluded platelet-
polyP not to be a physiologically relevant FXII activator (Faxalv et al., 2013). 
Since then, another study has found that platelet-size polyP only has minor 
direct effects on FXII, but that it can accelerate FXII activation by PK (Wang 
et al., 2019). In paper III, we found that neutrophil-induced vascular leakage, 
previously found to involve the KKS, is decreased with a polyP inhibitor and 
that polyP induces neutrophil degranulation. Given ours and others findings, 
it is intriguing to speculate that the role of platelet polyP in causing vascular 
leakage, besides the direct effects on EC, is by both KKS activation and by 
direct effects on neutrophils that in turn activates the KKS (Figure 7). An 
additional hypothesis is that polyP-mediated KKS activation leads to BK-
mediated neutrophil activation, which is supported by findings that 
neutrophils express BK receptors (Bockmann and Paegelow, 2000) and that 
LPS-induced neutrophil-platelet aggregation could be prevented with a BK 
receptor antagonist (Hou et al., 2018). In line with our findings, Hou and 
colleagues also found that platelet polyP activates neutrophils.  
In conclusion, paper III shows that polyP activates neutrophils and is 
involved in causing lung vascular leakage in acute systemic inflammation.  
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Figure 7. Suggested pathways for neutrophil activation and neutrophil-induced 
increases in endothelial permeability. A) Neutrophil adhesion to endothelial cells, B) 
streptococcal M protein-fibrinogen complex bind β2 integrins, C) platelet-induced neutrophil 
activation (receptor-mediated or paracrine effect with e.g. polyphosphates (polyP)), D) 
neutrophil degranulation, E) neutrophil extracellular trap (NETs) formation, F) granule 
proteins activate the kallikrein-kinin system with consequent bradykinin (BK) formation, G) 
platelet polyP has direct effects on endothelial cells and/or activates the kallikrein-kinin 
system. 
 
 
4.5 PHENYLBUTYRATE TREATMENT MODULATES THE 
HOST RESPONSE IN PSEUDOMONAS AERUGINOSA-
INDUCED PULMONARY INFLAMMATION 
In paper IV the aim was to study the effects of phenylbutyrate (PBA) on the 
inflammatory response in a mouse model of pulmonary inflammation with 
heat-killed Pseudomonas aeruginosa (hkPAO1). The short-chain fatty acid 
(SCFA) PBA is in clinical use for treatment of urea cycle disorders, and by its 
capacity to reduce endoplasmic reticulum stress and as a histone deacetylase 
inhibitor it is used for treatment in type-2 diabetes and various forms of 
cancer. Furthermore, PBA has both anti-inflammatory and host defense-
enhancing properties, and is suggested as a therapeutic in infectious disease 
(Coussens et al., 2015). 
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Inflammation was induced by intranasal instillation of hkPAO1 with or 
without PBA, and after incubation for different time periods mice were 
sacrificed and bronchoalvelolar lavage (BAL) fluid was analyzed for leukocyte 
content. HkPAO1 induced lung neutrophil recruitment, and treatment with 
PBA altered the kinetics of neutrophil influx to the lungs. At 4 h, neutrophil 
recruitment was significantly increased in PBA-treated mice compared to 
vehicle, and at 24 h it was significantly decreased (Figure 8A). Since the 
kinetics of neutrophil influx and consecutive clearance appeared faster with 
PBA treatment, the inflammatory edema in lungs was evaluated. Protein 
levels in BAL fluid and edema formation in lung tissue, assessed by wet-dry 
weight of whole lung, were decreased in PBA-treated mice 48 h post bacterial 
instillation (Figure 8B-C). These results support previous studies showing 
that PBA has anti-inflammatory effects (Ono et al., 2017, Kim et al., 2013).  
 
 
Figure 8. Phenylbutyrate (PBA) modulates the kinetics of the host response in 
hkPAO1-induced pulmonary inflammation in mice. A) Neutrophil accumulation in 
BAL fluid of mice subjected to intranasal administration of hkPAO1 at several time points 
with or without treatment with PBA. B) Protein levels in BAL fluid and C) wet-dry weight of 
lung tissue at T=0 and 48 hours after stimulation with hkPAO1. D and E) Chemotaxis assay 
with human isolated neutrophils showing that PBA does not have D) direct chemotactic 
activity, but E) stimulate lung epithelium to release factors that induce neutrophil 
chemotaxis. FBSi = heat-inactivated fetal bovine serum. 
 
 
SCFAs were previously shown to have direct chemotactic properties towards 
neutrophils (Vinolo et al., 2011), and since neutrophil recruitment was 
increased at 4 h in PBA-treated mice, PBA’s chemotactic potential was 
investigated. Intranasal treatment with PBA in unstimulated mice did not 
increase neutrophil recruitment as measured in BAL fluid, and an in vitro 
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chemotaxis assay showed no increase in migration towards PBA in the 
presence of hkPAO1 (Figure 8D). However, supernatant from cultured lung 
epithelium treated with PBA and hkPAO1 increased neutrophil migratory 
capacity, suggesting that PBA induces release of chemotactic factors from 
lung epithelium that could explain our findings in vivo (Figure 8E). Two 
typical neutrophil chemoattractants potentially involved are CXCL1 (mouse 
homologue of IL-8) and LTB4, but gene expression analysis of Cxcl1 and 
Alox5 in homogenized whole lung tissue showed no difference between PBA-
treated and vehicle mice.  
PBA has previously been found to enhance host defense by increasing 
expression of antimicrobial peptides (AMPs) such as the cathelicidin LL-37 
(Steinmann et al., 2009, Mily et al., 2013, Sarker et al., 2011). For that 
matter, gene expression of cathelicidin-related AMP (Cramp), the mouse 
homologue to cathelicidin, was measured in homogenized whole lung tissue 
at several time-points following hkPAO1-instillation with and without PBA. 
However, no significant increase was found in hkPAO1-stimulated mice and 
PBA did not alter the expression. Since PBA treatment dampened the 
inflammatory response at later time points, we hypothesized that PBA might 
expedite resolution of inflammation and therefore we measured the anti-
inflammatory cytokine IL-10 in BAL fluid and the gene expression of Alox15 
in lung tissue. Alox15 encodes 15-LOX, which mediates the formation of the 
pro-resolving lipoxins. IL-10 was not detected in BAL fluid and Alox15 
expression was unchanged at all time points. Gene expression of Ptgs2 
(COX-2) was also measured in lung tissue, and PBA-treated mice had 
significantly decreased expression of COX-2 at 4 h, supporting an anti-
inflammatory role of PBA.  
In summary, in a pulmonary inflammatory response caused by hkPAO1, PBA 
modulates the kinetics of the cellular host response by enhancing initial 
neutrophil recruitment, supposedly by stimulating lung epithelium to release 
chemotactic factors, and then causing a faster decline in neutrophil influx 
coincident with an attenuation of lung damage.  
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Major conclusions drawn based on the experimental work that makes up this 
thesis: 
 
§ The kallikrein-kinin system is involved in mediating neutrophil-induced 
vascular leakage in acute inflammation (paper I) 
 
§ The neutrophil-derived protein HBP act in concert with neutrophil serine 
proteases to activate the kallikrein-kinin system causing endothelial 
barrier disruption (paper I) 
 
§ Heparinoid sevuparin inhibits lung plasma leakage in hkGAS-induced 
acute systemic inflammation by neutralizing neutrophil-derived proteins 
(paper II) 
 
§ Platelet-derived polyphosphates activate neutrophils and contribute to 
neutrophil-induced lung plasma leakage in acute systemic inflammation 
(paper III) 
 
§ Phenylbutyrate treatment modulates the host response in pulmonary 
inflammation caused by hkPAO1 by altering the kinetics of neutrophil 
recruitment and by attenuating pulmonary edema (paper IV) 
 
Neutrophils are key players in infectious and inflammatory conditions such 
as ALI/ARDS. This thesis work present data confirming the central role of 
neutrophils in mediating inflammatory vascular leakage, and provides 
additional insights into mechanisms regulating neutrophil activation and 
endothelial barrier permeability. Targeting different functions of neutrophils 
might prove successful for improving outcome in inflammatory disease 
conditions. As of today, several different strategies are employed to treat 
inflammatory disease. One is to attack the stimuli that trigger the 
inflammatory reaction, e.g. with antibiotics or antivirals if the cause is 
infectious. Another option, complementary to the use of antibiotics and 
highly relevant due to the increase in antibiotic resistance, is to enhance the 
host response with immune modulators. In paper IV, the previously 
suggested immune modulator PBA was found to both accelerate the 
inflammatory response and to have anti-inflammatory effects in a murine 
model of pulmonary inflammation. Immune modulation for treatment of 
infection and for improving resolution of inflammation is a promising 
strategy with great potential. In non-infectious inflammatory disease, a 
common strategy is to counteract the inflammatory reaction by inhibiting the 
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production or activity of inflammatory mediators. In this thesis, various 
mediators of neutrophil-induced plasma leakage (Figure 7) were effectively 
antagonized with different pharmacological inhibitors. A possible advantage 
with this treatment strategy, as compared to more generalized anti-
inflammatory treatments, is that selectively targeting an inflammatory 
mediator may leave other functions of host defense intact. In support for this 
view we find that the neutrophils ability to adhere to EC and to extravasate to 
surrounding tissue is not seemingly impaired following inhibition of KKS 
constituents or treatment with sevuparin in paper I and II. These results 
might indicate a preserved cellular immune response whilst tissue is 
protected from excessive edema, suggesting that these treatment strategies 
could be beneficial as a complement to anti-infectious treatment in 
pathogen-induced inflammatory disease where the inflammatory response 
strongly contributes to morbidity and mortality.  
This thesis has focused on the role of neutrophils in acute inflammation, and 
has investigated the involvement of both platelets and the kallikrein-kinin 
system in this context. That several mechanisms of inflammation and 
coagulation are intertwined is becoming more and more clear, and new 
insights into the roles of the different players, namely neutrophils, platelets, 
coagulation factors, the kallikrein-kinin system and the endothelium, will 
lead to better understanding of these processes and hopefully to improved 
treatment strategies. Besides acting as a selective barrier between blood and 
tissue, the endothelium is also a thromboregulator that in health maintains 
an anti-thrombotic state. In inflammatory conditions such as sepsis, the 
endothelium increases expression of adhesion molecules and release factors 
that promote activation of neutrophils and platelets, as well as coagulation 
factors. Intravascular activation of the host response system leads to 
thromboinflammation that involves, amongst others, the aforementioned 
players (Ekdahl et al., 2016). In a recent study investigating the role of 
neutrophils in thromboinflammation, platelet polyP was found to induce 
NET formation (Chrysanthopoulou et al., 2017), and in paper III we found 
that polyP induces neutrophil degranulation and neutrophil-induced lung 
plasma leakage. The host defense mechanism immunothrombosis, involving 
activation of neutrophils, platelets and coagulation factors, is important for 
successfully combating intravascular pathogens by capture in microthrombi. 
However, exaggerated neutrophil activation in sepsis can cause uncontrolled 
immunothrombosis progressing into DIC (Stiel et al., 2018). Furthermore, a 
recent study proposed bacterial-type long-chain polyP as a factor for 
development of DIC by inducing FXII-dependent platelet aggregation and 
consumption (Zilberman-Rudenko et al., 2018). Taken together this suggests 
that inhibitors targeting polyP of both platelet and bacterial origin might be a 
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treatment strategy for conditions involving both inflammation and 
coagulation. 
Heparin, due to pleiotropic effects on both coagulation and inflammation, is 
a promising candidate as a therapeutic in inflammatory disease conditions 
such as sepsis (Li and Ma, 2017). In paper II, sevuparin attenuated lung 
plasma leakage in hkGAS-induced acute systemic inflammation. Unlike 
heparin, sevuparin lacks anticoagulant effects and might therefore be 
advantageous with regards to the risk of adverse bleeding. However, in sepsis 
with coagulopathy, heparin may be beneficial. Further studies investigating 
the effects of heparin, sevuparin and other low-anticoagulant derivatives in 
acute systemic inflammatory conditions are anticipated.  
The studies within this thesis were carried out in animal and cell culture-
based models of both noninfectious and infectious inflammatory conditions. 
In patients with e.g. ARDS there are numerous factors that differ from 
experimental models and that might influence treatment efficacy. For 
example, it may vary if the cause is infectious or noninfectious, and if 
infectious it matters which pathogen that is responsible. That neutrophils 
respond differently in terms of degranulation and NET formation towards 
different bacterial strains has previously been shown (Snall et al., 2016, 
Bystrzycka et al., 2018). In this thesis work, effects on survival with different 
treatments were not investigated, and only heat-killed bacterial strains were 
used so assessment of bacterial dissemination was not feasible. It ought to be 
emphasized also that treatment during an already established inflammatory 
response was not tested. In a clinical context, pre-treatment does not occur 
and therefore the time-dependent efficacy is also a factor that warrants 
further examination. 
To sum up this thesis I would like to end with a definition of inflammation by 
Mauricio Rocha e Silva that I think encapsulates its complexity: “a multi-
mediated phenomenon, of a pattern type in which all mediators would come 
and go at the appropriate moment to play their roles in increasing vascular 
permeability, attracting leucocytes, producing pain, local edema and 
necrosis, in which the predominance of any would be fortuitous or depending 
on its specific capabilities of producing symptoms, some directly, some 
indirectly, some by potentiating or by releasing other agents” (Silva, 1978). 
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